Composition and methods for treating Alzheimer&#39;s disease and other amyloidoses

ABSTRACT

A method of treating an amyloid disease in a patient or inhibiting the formation, deposition, accumulation, or persistence, of amyloid fibrils, amylin fibrils, or islet amyloid fibrils, and/or dissolving or disrupting pre-formed or pre-deposited amyloid fibrils in type II diabetes in a mammalian subject. In the method a therapeutically effective amount of plant matter form the genus  Uncaria , species  Tomentosa  is administered, preferably from the inner bark or root tissue of  Uncaria Tomentosa.

This is a divisional of application Ser. No. 10/610,346 filed Jun. 30,2003, now abandoned, which is a divisional of application Ser. No.09/938,987 filed Aug. 24, 2001, now U.S. Pat. No. 6,607,758, which is acontinuation of application Ser. No. 09/079,829, now U.S. Pat. No.6,939,570, filed May 15, 1998 which claims priority to provisionalpatent application Ser. No. 60/046,602 filed May 15, 1997.

TECHNICAL FIELD

The invention relates to compositions and methods for treatingAlzheimer's Disease and other amyloidoses, and to methods for isolatingpharmacological agents from plant matter; more particularly, it relatesto compositions and methods for therapeutic intervention in Alzheimer'sdisease and other amyloidoses and methods for isolation of andidentification of amyloid inhibitory ingredients within plant matter.

BACKGROUND OF THE INVENTION

Alzheimer's disease is characterized by the accumulation of a 39-43amino acid peptide termed the beta-amyloid protein or Aβ, in a fibrillarform, existing as extracellular amyloid plaques and as amyloid withinthe walls of cerebral blood vessels. Fibrillar Aβ amyloid deposition inAlzheimer's disease is believed to be detrimental to the patient andeventually leads to toxicity and neuronal cell death, characteristichallmarks of Alzheimer's disease. Accumulating evidence implicatesamyloid as a major causative factor of Alzheimer's disease pathogenesis.

A variety of other human diseases also demonstrate amyloid depositionand usually involve systemic organs (i.e. organs or tissues lyingoutside the central nervous system), with the amyloid accumulationleading to organ dysfunction or failure. In Alzheimer's disease and“systemic” amyloid diseases, there is currently no cure or effectivetreatment, and the patient usually dies within 3 to 10 years fromdisease onset.

Much work in Alzheimer's disease has been accomplished, but little isconventionally known about compounds or agents for therapeutic regimesto arrest amyloid formation, deposition, accumulation and/or persistencethat occurs in Alzheimer's disease and other amyloidoses.

New compounds or agents for therapeutic regimes to arrest or reverseamyloid formation, deposition, accumulation and/or persistence thatoccurs in Alzheimer's disease and other amyloidoses are thereforedesperately needed.

DISCLOSURE OF THE INVENTION

A primary object of the present invention is to establish new methodsfor the treatment of the amyloid diseases. The amyloid diseases include,but are not limited to, the amyloid associated with Alzheimer's disease,Down's syndrome and hereditary cerebral hemorrhage with amyloidosis ofthe Dutch type (wherein the specific amyloid is referred to asbeta-amyloid protein or Aβ), the amyloid associated with chronicinflammation, various forms of malignancy and Familial MediterraneanFever (wherein the specific amyloid is referred to as AA amyloid orinflammation-associated amyloidosis), the amyloid associated withmultiple myeloma and other B-cell dyscrasias (wherein the specificamyloid is referred to as AL amyloid), the amyloid associated with typeII diabetes (wherein the specific amyloid is referred to as amylin orislet amyloid), the amyloid associated with the prion diseases includingCreutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru andanimal scrapie (wherein the specific amyloid is referred to as PrPamyloid), the amyloid associated with long-term hemodialysis and carpaltunnel syndrome (wherein the specific amyloid is referred to asbeta₂-microglobulin amyloid), the amyloid associated with senile cardiacamyloid and Familial Amyloidotic Polyneuropathy (wherein the specificamyloid is referred to as transthyretin or prealbumin), and the amyloidassociated with endocrine tumors such as medullary carcinoma of thethyroid (wherein the specific amyloid is referred to as variants ofprocalcitonin).

Another object of the present invention is to use the inner bark and/orroots from Uncaria tomentosa (also referred to as Uña de Gato or Cat'sclaw) for the treatment of amyloid formation, deposition, accumulationand/or persistence in Alzheimer's disease, type II diabetes and otheramyloidoses. Uncaria tomentosa or Cat's claw is also referred to as, butnot limited to, Paraguayo, Garabato, Garbato casha, Tambor huasca, Unade gavilan, Hawk's claw, Nail of Cat, and Nail of Cat Schuler.

Another object of the present invention is to use extracts and/orderivatives thereof from plant matter related to the Rubiciaceae family,which includes but is not limited to the Uncaria genus, for thetreatment of amyloid formation, deposition, accumulation and/orpersistence in Alzheimer's disease, type II diabetes and otheramyloidoses.

Another object of the present invention is to use extracts and/orderivatives thereof from plant matter related to the various Uncariaspecies, which may include but not limited to, Uncaria tomentosa,Uncaria attenuate, Uncaria elliptica, Uncaria guianensis, Uncariapteropoda, Uncaria bernaysli, Uncaria ferra DC, Uncaria kawakamii,Uncaria rhyncophylla, Uncaria calophylla, Uncaria gambir, and Uncariaorientalis.

Another object of the present invention is to use commercially availablepills, tablets, caplets, soft and hard gelatin capsules, lozenges,sachets, cachets, vegicaps, liquid drops, elixers, suspensions,emulsions, solutions, syrups, tea bags, aerosols (as a solid or in aliquid medium), suppositories, sterile injectable solutions, sterilepackaged powders, bark bundles and/or bark powder which contain Uncariatomentosa to treat patients with Alzheimer's disease, type II diabetesand other amyloidoses.

Another object of the present invention is to use Uncaria tomentosaand/or the oxindole alkaloids contained within Uncaria tomentosa for thetreatment of amyloid formation, deposition, accumulation and/orpersistence in Alzheimer's disease, type II diabetes and otheramyloidoses.

Yet another object of the present invention is to use the quinovic acidglycosides contained within Uncaria tomentosa for the treatment ofamyloid formation, deposition, accumulation and/or persistence inAlzheimer's disease, type II diabetes and other amyloidoses.

Yet another object of the present invention is to use theproanthocyanidins contained within Uncaria tomentosa for the treatmentof amyloid formation, deposition, accumulation and/or persistence inAlzheimer's disease, type II diabetes and other amyloidoses.

Yet another object of the present invention is to use the polyphenolscontained within Uncaria tomentosa for the treatment of amyloidformation, deposition, accumulation and/or persistence in Alzheimer'sdisease, type II diabetes and other amyloidoses.

Yet another object of the present invention is to use the triterpinescontained within Uncaria tomentosa for the treatment of amyloidformation, deposition, accumulation and/or persistence in Alzheimer'sdisease, type II diabetes and other amyloidoses.

Yet another object of the present invention is to use the plant sterols,beta-sitosterol, stigmasterol and campesterol contained within Uncariatomentosa for the treatment of amyloid formation, deposition,accumulation and/or persistence in Alzheimer's disease, type II diabetesand other amyloidoses.

Yet another object of the present invention is to use the phytosterolscontained within Uncaria tomentosa for the treatment of amyloidformation, deposition, accumulation and/or persistence in Alzheimer'sdisease, type II diabetes and other amyloidoses.

Yet another object of the present invention is to use one or more of thephytochemicals contained within Uncaria tomentosa, or its constituentcompounds, for the treatment of amyloid formation, deposition,accumulation and/or persistence in Alzheimer's disease, type II diabetesand other amyloidoses. These constituents are believed to include, butnot be limited to, 3-beta, 6beta,19-alpha-trihydroxy-urs-12-en-28-oic-acid, 5-alpha-carboxystrictosidine,Alloisopteropodine, Allopteropodine, Angustine, Dihydrocorynantheine,Dihydrocorynantheine-n-oxide, Hirsutine, Hirsutine-n-oxide,Isomitraphylline, Isopteropodine, Isorhynchophylline,Isorhynchophylline-n-oxide, Isorotundifoline, Mitraphylline,Oleanolic-acid, Pteropodine,Quinovic-acid-3beta-o-(Beta-d-glucopyranosyl-(1→3)beta-d-fucopyranosyl-(27→1)betad-glucopyranosyl-ester, Quinovic-acid-3beta-o-beta-d-fucopyranoside,Quinovic-acid-3beta-o-beta-d-fucopyranosyl-(27→1)beta-d-glucopyranosylester,Quinovic-acid-3beta-o-beta-d-quinovopyranoside, Rhynchophylline,Rotundifoline, Speciophylline, Uncarine, Uncarine-f, and Ursolic acid.

Yet another object of the present invention is to use other knownphytochemicals previously identified by Keplinger as possibly useful forstimulating the human immune system. These include alkaloid, phenol,quinone and terpene based compounds disclosed in U.S. Pat. No. 4,844,901and U.S. Pat. No. 4,940,725 by Keplinger et al, the texts of which arehereby incorporated by reference, and include, but are not limited to,tetra- and pentacyclic oxindole alkaloids, alkaloids such asalloisopteropodine, isomer A having the formula C₂₁H₂₄O₄N₂,allo-pteropodine, isomer B having the formula C₂₁H₂₄O₄N₂,normal-isomitraphylline, isomer A having the formula C₂₁H₂₄O₄N₂,normal-isorhychophylline, isomer A having the formula C₂₂H₂₈O₄N₂,normal-mitraphylline, isomer B having the formula C₂₁H₂₄O₄N₂,normal-rhynchophyllin isomer B having the formula C₂₂H₂₈O₄N₂, and theoxindole alkaloid speciophylline, Cepharanthine (bisbenzylisochinolinealkaloid), Berbamine (bisbenzylisochinoline alkaloid), Matrine (lupinealkaloid), Pilocarpine (imidazole alkaloid), phenols and quinones suchas 2,3-Dihydroxybenzoic acid, Ferulic acid, Anethole, Cleistanthine(lignane), Curculigoside and Curculigoside B (phenolglucosides),Urunshiole (pyrocatechin derivatives with C₁₅/C₁₇ side chains,alpha-Tocopherole (vitamin E), Ubichone (mainly Q7, Q8), Maesanine(chinone with C₁₅-side-chain), terpenes such as Zexbrevine A/B(sesquiter-penelacetone of the ceramacrane type),12-O-Tetradeoanoyl-phorbol-13-acetate, TPA (tetracyclic diterpene),Saponine with aglycone oleonic acid (pentacyclic triterpene), andCynonchoside (steroidglycoside).

Yet another object of the present invention is to provide methods toisolate the active ingredients present within Uncaria tomentosa for useas potent agents which inhibit amyloid formation, amyloid deposition,amyloid accumulation, amyloid persistence, amyloid protein-amyloidprotein interactions, and/or cause a dissolution/disruption ofpre-formed or pre-deposited amyloid fibrils in Alzheimer's disease, typeII diabetes and other amyloidoses. Methods for isolation of the activeingredients within Uncaria tomentosa include application of somestandard techniques known to those skilled in the art, including, butnot limited to, thin layer chromatography using silica-coated plates,and separation and isolation using high pressure liquid chromatography(HPLC). Unknown active ingredients within Uncaria tomentosa found to bepotent inhibitors of amyloid formation, amyloid deposition, amyloidaccumulation, amyloid persistence, amyloid protein-amyloid proteininteractions, and/or cause a dissolution/disruption of pre-formed orpre-deposited amyloid fibrils in Alzheimer's disease, type II diabetesand other amyloidoses, are identified by re-testing of individual bandsor fractions (separated by thin layer chromatography, columnchromatography and/or HPLC) using specific assay tests as described inthe examples of the present invention. Sufficient isolation of theseactive ingredients contained within individual bands and/or fractionsare then sent out for specific analyses which may include, but are notlimited to, scanning electron microscope equipped with energy dispersivex-ray analyzer to detect and spatially map some elements present in eachsample, elemental analysis by combustion to determine the relative % ofcarbon, hydrogen and nitrogen, high resolution mass spectroscopy todetermine molecular weight and elemental composition, fourier transforminfrared spectroscopy to determine functional groups and makecomparisons to the spectra of known compounds, differential scanningcalorimetry to determine melting point, atomic absorption, gelchromatography, high performance liquid chromatography, proton and C¹³nuclear magnetic resonance spectroscopy for material characterizationand to provide information regarding the position of atoms relative toeach other, and UV/VIS spectroscopy. It is expected that additionaltechniques will be developed as part of the further isolation of potentactive ingredients within Uncaria tomentosa.

Yet another object of the present invention is to provide the use ofUncaria tomentosa and/or its ingredients [(regardless of commercialsource and regardless of final form for consumption by humans, i.e.pills, tablets, caplets, soft and hard gelatin capsules, lozenges,sachets, cachets, vegicaps, liquid drops, elixers, suspensions,emulsions, solutions, syrups, tea bags, aerosols (as a solid or in aliquid medium), suppositories, sterile injectable solutions, sterilepackaged powders, bark bundles and/or bark powder] for inhibition ofamyloid formation, deposition, accumulation, and/or persistence,regardless of its clinical setting.

Yet another object of the present invention is to provide compositionsand methods involving administering to a subject a therapeutic dose ofUncaria tomentosa (or its active ingredients) which inhibits amyloiddeposition. Accordingly, the compositions and methods of the inventionare useful for inhibiting amyloidosis in disorders in which amyloiddeposition occurs. The compounds of the invention can be usedtherapeutically to treat amyloidosis or can be used prophylactically ina subject susceptible to amyloidosis. The methods of the invention arebased, at least in part, in directly inhibiting amyloid fibrilformation, inhibiting amyloid fibril growth, and/or causingdissolution/disruption of preformed amyloid fibrils.

Yet another object of the present invention is to provide pharmaceuticalcompositions for treating amyloidosis. The pharmaceutical compositionsinclude a therapeutic compound of the invention in an amount effectiveto inhibit amyloid deposition and a pharmaceutically acceptable vehicle.

Yet another object of the present invention is the use of any and allsynthetic compounds made that are functionally similar to Uncariatomentosa in therapeutic application, and/or Uncaria tomentosa's amyloidinhibitory ingredients, for use as agents to inhibit amyloid formation,amyloid deposition, amyloid accumulation, amyloid persistence, amyloidprotein-amyloid protein interactions, and/or cause adissolution/disruption of pre-formed or pre-deposited amyloid fibrils inAlzheimer's disease, type II diabetes and other amyloidoses.

It is yet another object of the invention to meet any or all of theneeds summarized above.

These and such other objects of the invention as will become evidentfrom the disclosure below are met by the invention disclosed herein.

Application of the invention to these needs is especially beneficial inthat the invention is the only system that effectively provides for useof extracts from the inner bark and root parts of Uncaria tomentosa, anduse of the ingredients contained within the various commercialpreparations of Uncaria tomentosa, to benefit human patients withAlzheimer's disease and other amyloidoses due to Uncaria tomentosa'snewly discovered ability to inhibit amyloid fibril formation, inhibitamyloid fibril growth, inhibit amyloid-proteoglycan interactions,amyloid-glycosaminoglycan interactions, and cause dissolution and/ordisruption of preformed amyloid fibrils.

The present invention pertains to the identification and surprisingdiscovery that the inner bark and root parts of Uncaria tomentosa,otherwise known as Uña de Gato (or Cat's claw), act as an inhibitor ofAlzheimer's disease amyloid formation and growth. In addition, Uncariatomentosa also has the ability to inhibit amyloid protein-proteoglycan(PG)/glycosaminoglycan (GAG) interactions, which are believed to beimportant for the formation and persistence of all amyloid deposits intissues. Furthermore, Uncaria tomentosa has the ability todissolve/disrupt pre-formed amyloid fibrils of the Alzheimer's and typeII diabetes types, suggesting that this agent may be useful for patientsat latter stages of both Alzheimer's disease, type II diabetes and otheramyloidoses. Uncaria tomentosa extracted from different commercialsources (extracts isolated from gelatin-coated capsules, caplets orliquid form) were all found to serve as potent inhibitors of Alzheimer'sdisease amyloid fibrillogenesis.

While results are exemplified with Species tomentosa, other species ofUncaria are believed to have similar effect.

Commercially available glucosamine (hydrochloride salt, or the sulfatesalt), which contained Uncaria tomentosa caused a marked significantinhibition of Aβ amyloid fibril formation as determined using aThioflavin T fluorometry assay. This inhibitory effect was attributed tothe presence of Uncaria tomentosa (and not due to the presence ofglucosamine hydrochloride salt or to the glucosamine sulfate salt), aspure Uncaria tomentosa (but not pure glucosamine hydrochloride salt orglucosamine sulfate salt) derived from different commercial sources werepotent inhibitors of amyloid fibril formation. Uncaria tomentosa(without other additives) obtained from different commercial sourcesinhibited Aβ amyloid fibrillogenesis in a dose-dependent manner. Uncariatomentosa also inhibited Alzheimer's Aβ-Aβ interactions as determinedusing a solid phase binding assay demonstrating that Uncaria tomentosais additionally an effective inhibitor of Alzheimer's amyloid fibrilgrowth. Furthermore, Uncaria tomentosa was effective in thedose-dependent inhibition of Aβ-proteoglycan/glycosaminoglycan (PG/GAG)interactions (an important therapeutic target for all amyloidoses) asdetermined using a solid phase binding immunoassay. Uncaria tomentosaderived from different commercial sources was also a potentdissolving/inhibiting agent of pre-formed Aβ (1-40) or Aβ (1-42)containing amyloid fibrils, as determined using Thioflavin T fluorometryand Congo red staining assays. This latter effect occurred in adose-dependent manner, causing a significant (p<0.001) 70% dissolutionwithin a 2 hour incubation period. In addition, Uncaria tomentosa was apotent dissolving agent of islet amyloid fibrils (ie. amylin), causing a72% dissolution within a 2 hour incubation period, and a 80% dissolutionby 4 days. Uncaria tomentosa which was effective in all of the studiesdescribed above were all derived from Uncaria tomentosa extract obtainedfrom pill, tablet or liquid form, and were all currently availablecommercially for oral use in humans. Therefore, the present inventionclaims the use of Uncaria tomentosa (in a pill, tablet or liquid form)and derivatives thereof from different commercial sources for thetreatment of amyloidosis in Alzheimer's disease, type II diabetes andother amyloidoses. Also disclosed are methods of isolation to identifyand purify the key amyloid inhibitory ingredients within the plantmaterial. Identification of the “active” amyloid inhibitory ingredientswithin the extracted plant materials are anticipated to lead to new drugdesign for anti-amyloid therapeutics of the future. Current use ofUncaria tomentosa and its ingredients contained within differentcommercial preparations are anticipated to benefit human patients at allstages of Alzheimer's disease due to Uncaria tomentosa's inherentability to inhibit Aβ amyloid fibril formation (early to mid-stageAlzheimer's disease), inhibit amyloid fibril growth (early to mid-stageAlzheimer's disease), inhibit amyloid-PG/GAG interactions (all stages ofAlzheimer's disease) and cause dissolution/disruption of preformedamyloid fibrils (mid to late stages of Alzheimer's disease). Similarly,Uncaria tomentosa is anticipated to benefit patients with differentsystemic amyloid diseases such as type II diabetes, regardless of thestage of amyloid accumulation and the organ (or tissue) involved.

In another particular aspect of the invention there is a method ofisolation to purify and identify the amyloid inhibitory ingredients fromUncaria tomentosa and/or extracts thereof. In one such method, anextract prepared from commercially obtained pills, tablets, caplets,soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps,liquid drops, elixers, suspensions, emulsions, solutions, syrups, teabags, aerosols (as a solid or in a liquid medium), suppositories,sterile injectable solutions, sterile packaged powders, bark bundlesand/or bark powder, using the method employing some or all of thefollowing steps:

a) extraction from Uncaria tomentosa regardless of form as describedabove using an organic solvent such as propanol, b) concentration of theextract by using a method such as rotary evaporation, lyophilization orprecipitation, c) centrifugation of the extract to remove insolublematerials, d) recentrifugation of the supernatant to further removeinsoluble material, e) precipitation of the active ingredients using anorganic solvent such as petroleum ether followed by centrifugation, f)re-dissolving the pellet obtained in an organic solvent such aspropanol, g) applying to a silica column equilibrated with propanol/10%acetic acid and eluting with the same solvent, h) collecting thefastest-moving fraction (orange/brown-yellow colored fractions) asdetermined by sight or by monitoring at 490 nm, i) precipitation of theactive components using an organic solvent such as petroleum ether,followed by centrifugation, j) re-dissolving the pellet obtained inacetonitrile/water/acetic acid, and k) injecting and separation by HPLC,l) identifying amyloid inhibitory ingredients by testing in relevant invitro and in vivo assays, and m) sending out for structural analysis andelemental composition, as described herein.

These and other features and advantages of the present invention willbecome more fully apparent when the following detailed description ofthe invention is read in conjunction with the accompanying figures.

In other aspects of the invention, a pharmaceutical agent is disclosedfor treating an amyloid disease in a patient, wherein thepharmacological agent comprises a therapeutically effective amount ofplant matter from a plant of the genus Uncaria. The pharmacologicalagent is preferably from a plant of the genus Uncaria, speciestomentosa. The pharmacological agent is preferably an extract obtainedfrom Uncaria tomentosa, the extract being derived from the inner bark orroot tissue of Uncaria tomentosa, and advantageously taken from somecommercially available source, such as pills, tablets, caplets, soft andhard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquiddrops, elixers, suspensions, emulsions, solutions, syrups, tea bags,aerosols (as a solid or in a liquid medium), suppositories, sterileinjectable solutions, sterile packaged powders, bark bundles or barkpowder.

In preferred embodiments, the pharmacological agent is an amyloidinhibitory ingredient selected from the group consisting of oxindolealkaloids, quinovic acid glycosides, proanthocyanidins, polyphenols,triterpines, plants sterols, beta-sitosterol, stigmasterol, campesterol,phytosterols, 3-beta, 6beta, 19alpha-trihydroxy-urs-12-en-28-oic-acid,5alpha-carboxystrictosidine, alloisopteropodine, allopteropodine,angustine, dihydrocorynantheine, dihydrocorynantheine-n-oxide,hirsutine, hirsutine-n-oxide, isomitraphylline, isopteropodine,isorhynchophylline, isorhynchophylline-n-oxide, isorotundifoline,curculogoside, curculigoside B, phenolglucosides,2-[[2,6-dimethoxybenzoyl)oxy]methyl-4-hydroxyphenyl-beta-D-glucopyranoside,2-[[2-hydroxy-6-methoxybenzoyl)oxy]methyl-4-hydroxyphenyl-beta-D-glucopyranoside,mitraphylline, oleanolic-acid, pteropodine,quinovic-acid-3beta-o-(Beta-dglucopyranosyl-(1→3)beta-d-fucopyranosyl-(27→1)-betad-glucopyranosyl-ester, quinovic-acid-3beta-o-beta-d-fucopyranoside,quinovic-acid-3beta-o-beta-d-fucopyranosyl-(27→1)-beta-d-glucopyranosylester,quinovic-acid-3beta-o-beta-d-quinovopyranoside, rhynchophylline,rotundifoline, speciophylline, uncarine, uncarine-f, ursolic acid,cepharanthine (bisbenzylisochinoline alkaloid), berbamine(bisbenzylisochinoline alkaloid), matrine (lupine alkaloid), pilocarpine(imidazole alkaloid), 2,3-Dihydroxybenzoic acid, ferulic acid, anethole,cleistanthine (lignane), phenolglucosides, urunshiole, alpha-tocopherole(vitamin E), ubichone, maesanine, zexbrevine A/B,12-O-tetradeoanoyl-phorbol-13-acetate, TPA (tetracyclic diterpene),saponine with aglycone oleonic acid (pentacyclic triterpene), andcynonchoside.

The pharmacological agent preferably has a therapeutically effectiveamount of Uncaria tomentosa in a dosage in the range of from about 10 to1,000 mg/kg of body weight of the patient, and more preferably in therange of from about 10 to 100 mg/kg of body weight of the patient.

The amyloid disease for treatment with the pharmacological agent isselected from the group consisting of the amyloid associated withAlzheimer's disease, Down's syndrome and hereditary cerebral hemorrhagewith amyloidosis of the Dutch type (wherein the specific amyloid isreferred to as beta-amyloid protein or Aβ), the amyloid associated withchronic inflammation, various forms of malignancy and FamilialMediterranean Fever (wherein the specific amyloid is referred to as AAamyloid or inflammation-associated amyloidosis), the amyloid associatedwith multiple myeloma and other B-cell dyscrasias (wherein the specificamyloid is referred to as AL amyloid), the amyloid associated with typeII diabetes (wherein the specific amyloid is referred to as amylin orislet amyloid), the amyloid associated with the prion diseases includingCreutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru andanimal scrapie (wherein the specific amyloid is referred to as PrPamyloid), the amyloid associated with long-term hemodialysis and carpaltunnel syndrome (wherein the specific amyloid is referred to asbeta₂-microglobulin amyloid), the amyloid associated with senile cardiacamyloid and Familial Amyloidotic Polyneuropathy (wherein the specificamyloid is referred to as transthyretin or prealbumin), and the amyloidassociated with endocrine tumors such as medullary carcinoma of thethyroid (wherein the specific amyloid is referred to as variants ofprocalcitonin).

Preferred pharmaceutical agents have a weight percentage of plantextract in the agent is in the range of from about 70% to about 95%, andmay also have a pharmaceutically acceptable carrier, diluent orexcipient. The pharmaceutical agent preferably has an amyloid inhibitoryactivity or efficacy greater than 50%.

Another aspect of the invention is a method for isolating amyloidinhibitory constituents within Uncaria tomentosa plant matter, themethod comprising the following steps: a) extracting the plant matterwith an organic solvent, b) concentrating the extract, c) removinginsoluble materials, d) precipitating amyloid inhibitory constituentswith organic solvent e) recovering and redissolving the amyloidinhibitory constituents obtained in organic solvent, and f) injectingand separation by HPLC.

The plant matter is preferably comprised of commercially obtained pills,tablets, caplets, soft and hard gelatin capsules, lozenges, sachets,cachets, vegicaps, liquid drops, elixers, suspensions, emulsions,solutions, syrups, tea bags, aerosols (as a solid or in a liquidmedium), suppositories, sterile injectable solutions, sterile packagedpowders, bark bundles and/or bark powder, which contain Uncariatomentosa, extracts or derivatives thereof, and may be taken fromcommercially available gelatin-coated capsules which containdried-powder of Uncaria tomentosa, extracts or derivatives thereof.

The step of extracting the plant matter with an organic solvent furthercomprises adding propanol initially to plant materials that arepowdered, and the resulting mixture is stirred overnight. The solventused in the step of extracting amyloid inhibitory ingredients preferablyhas a polarity ranging from that of water to that of pentanol. The stepof removing insoluble materials is preferably effected by centrifugingthe extract and collecting the supernatant. The step of concentratingthe extract is preferably effected by rotary evaporation. Following theextraction and centrifugation steps, the extraction and centrifugationprocedure is preferably repeated 1-5 more times and the supernatants arecollected.

Following the repeated steps of extraction and concentration, thesupernatants are preferably pooled and concentrated using a rotaryevaporator. Following the concentrating step, and after the volume isabout 500 mls or less, the extract is preferably recentrifuged tofurther remove insoluble materials. Following the recentrifugation step,the supernatant is preferably obtained and precipitated with petroleumether, preferably 4 volumes. Following precipitation with petroleumether, the precipitate is preferably collected in a pellet followingfurther centrifugation. The pellet is then preferably dissolved inpropanol and applied to a silica column equilibrated with propanolcontaining acetic acid. Following the application of the material to asilica column, propanol containing acetic acid is used to elute, and thefastest moving yellowish-brown colored fractions are collected with afraction collector. The eluents from the column are preferably monitoredspectroscopically at 490 nm and fractions are collected in a fractioncollector. Following collection of the fastest moving yellowish-browncolored fractions, the fractions are precipitated with petroleum ether,and the precipitate is collected following centrifugation. Followingreprecipitation and recentrifugation, the pellet is dissolved inacetonitrile/acetic acid/water for high pressure liquid chromatography(HPLC) injection. The dissolved pellet is divided into equal portionsand injected into an HPLC. The HPLC used preferably contains a 1×25 cmC₁₈ column, though other sizes may be made to serve, and is maintainedat 30° C. with a flow rate of 2 ml/min. The sample portions injectedonto the HPLC are eluted with gradients of A and B, such that 0% B for 5minutes, 0-15% B from 5-10 minutes, 15-45% B from 10-70 minutes, and45-100% B from 70-85 minutes; where B=95% acetonitrile with 0.5% aceticacid in distilled water and A=5% acetonitrile with 0.5% acetic acid indistilled water. The eluents from the HPLC are monitored at 490 nm and 4ml fractions are collected in a fraction collector and pooled peaks areobtained at various retention times (from 0 through 85 minutes). Thefractions obtained may be concentrated by lyophilization after most ofthe acetonitrile is removed by rotary evaporation.

The concentrated fractions obtained are then tested in relevant in vitroassays to identify potent inhibitors of amyloid fibril formation,amyloid fibril growth or dissolution/disruption of pre-formed amyloidfibrils. The amyloid inhibitory ingredients within Uncaria tomentosa arepreferably drawn from the HPLC approximate HPLC retention times of 13-45minutes, and more preferably 26 minutes.

A method is also disclosed for treating an amyloid disease in a patient,comprising the step of administering to the patient a therapeuticallyeffective amount of plant matter from a plant of the genus Uncaria,species tomentosa. The plant matter is preferably administered orally orby aerosol spray or in a parenterally injectable or infusible form.

The therapeutically effective amount of plant matter is preferably anamyloid inhibitory ingredient selected from the group consisting ofoxindole alkaloids, quinovic acid glycosides, proanthocyanidins,polyphenols, triterpines, plants sterols, beta-sitosterol, stigmasterol,campesterol, phytosterols, 3-beta, 6beta,19alpha-trihydroxy-urs-12-en-28-oic-acid, 5alpha-carboxystrictosidine,alloisopteropodine, allopteropodine, angustine, dihydrocorynantheine,dihydrocorynantheine-n-oxide, hirsutine, hirsutine-n-oxide,isomitraphylline, isopteropodine, isorhynchophylline,isorhynchophylline-n-oxide, isorotundifoline, curculogoside,curculigoside B, phenolglucosides,2-[[2,6-dimethoxybenzoyl)oxy]methyl-4-hydroxyphenyl-beta-D-glucopyranoside,2-[[2-hydroxy-6-methoxybenzoyl)oxy]methyl-4-hydroxyphenyl-beta-D-glucopyranoside,mitraphylline, oleanolic-acid, pteropodine,quinovic-acid-3beta-o-(Beta-dglucopyranosyl-(1→3)beta-d-fucopyranosyl-(27→1)-beta-d-glucopyranosyl-ester,quinovic-acid-3beta-o-beta-d-fucopyranoside,quinovic-acid-3beta-o-beta-d-fucopyranosyl-(27→1)-beta-d-glucopyranosylester,quinovic-acid-3beta-o-beta-d-quinovopyranoside, rhynchophylline,rotundifoline, speciophylline, uncarine, uncarine-f, ursolic acid,cepharanthine (bisbenzylisochinoline alkaloid), berbamine(bisbenzylisochinoline alkaloid), matrine (lupine alkaloid), pilocarpine(imidazole alkaloid), 2,3-Dihydroxybenzoic acid, ferulic acid, anethole,cleistanthine (lignane), phenolglucosides, urunshiole, alpha-tocopherole(vitamin E), ubichone, maesanine, zexbrevine A/B,12-O-tetradeoanoyl-phorbol-13-acetate, TPA (tetracyclic diterpene),saponine with aglycone oleonic acid (pentacyclic triterpene), andcynonchoside.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a black and white graph of a 1 week Thioflavin T fluorometryassay utilized to identify inhibitors of Alzheimer's Aβ (1-40) amyloidfibril formation. Glucosamine (sulfate salt) containing Uncariatomentosa (PTI-00700) is shown to be a potent inhibitor of Aβ (1-40)amyloid fibril formation.

FIG. 2 is a black and white graph of a 1 week Thioflavin T fluorometryassay utilized to identify inhibitors of Alzheimer's Aβ (1-40) amyloidfibril formation. Glucosamine (sulfate salt) containing Uncariatomentosa (PTI-00700), glucosamine (sulfate salt) containing Uncariatomentosa (PTI-00700<30 kDa) which had gone through a filter withmolecular weight cutoff of 30 kDa (PTI-00700<30 kDa), glucosamine(hydrochloride salt) containing Uncaria tomentosa (PTI-00701), and pureUncaria tomentosa (PTI-00703) are all shown to be effective inhibitorsof Alzheimer's Aβ amyloid fibril formation.

FIG. 3 is a black and white graph of a solid phase binding assayutilized to identify lead compounds which inhibit Alzheimer's Aβ-Aβinteractions (i.e. Alzheimer's amyloid fibril growth). Glucosamine(sulfate salt) containing Uncaria tomentosa (PTI-00700) is identified asa potent inhibitor of Alzheimer's amyloid fibril growth.

FIG. 4 is a black and white graph of a solid phase binding immunoassayutilized to determine the potential dose-dependent effects ofglucosamine (sulfate salt) containing Uncaria tomentosa (PTI-00700) oninhibition of Aβ-proteoglycan/glycosaminoglycan (PG/GAG) interactions.Significant dose-dependent inhibition of Aβ-PG/GAG interactions isobserved with treatment of glucosamine (sulfate salt) containing Uncariatomentosa.

FIG. 5 is a black and white graph of a Thioflavin T fluorometry assayutilized to determine the potential dose-dependent effects of Uncariatomentosa extract (PTI-00703) on dissolution/disruption of pre-formedAlzheimer's Aβ (1-40) amyloid fibrils within a 2 hour incubation period.Uncaria tomentosa extract causes dissolution of pre-formed Alzheimer'sAβ amyloid fibrils in a dose-dependent manner.

FIG. 6 is a black and white graph of a Thioflavin T fluorometry assayutilized to show that Uncaria tomentosa extract obtained from anothercommercial source (referred to as PTI-00703-02), and from Uncariatomentosa in liquid form, is also able to cause significantdissolution/disruption of pre-formed Alzheimer's Aβ (1-40) amyloidfibrils within a 2 hour incubation period.

FIG. 7 is a black and white graph of a Thioflavin T fluorometry assayutilized to show that Uncaria tomentosa extract obtained from yetanother commercial source (referred to as PTI-00703-R) is able to causesignificant dose-dependent dissolution/disruption of pre-formedAlzheimer's Aβ (1-40) amyloid fibrils within a 2-hour incubation period.1/10,000th of the extract from Uncaria tomentosa contained within asingle gelatin-coated pill caused a significant (p<0.001) 58%dissolution, whereas 1/1,000th of a single pill Uncaria tomentosaextract caused a significant (p<0.001) 81% dissolution, 1/500th of asingle pill Uncaria tomentosa extract caused a significant (p<0.001) 93%dissolution, and 1/250th of a single pill Uncaria tomentosa extractcaused a significant (p<0.001) 97% dissolution.

FIG. 8 is a black and white graph of a Thioflavin T fluorometry assayutilized to show that an Uncaria tomentosa extract (PTI-00703) is alsoable to cause a significant (p<0.001) dissolution of pre-formedAlzheimer's Aβ (1-42) amyloid fibrils (i.e. the longer and morefibrillogenic form of Alzheimer's amyloid) at all time points, with a63% dissolution/inhibition observed as early as 2 hours of incubation.

FIG. 9 is a black and white graph of a Thioflavin T fluorometry assayutilized to show that an Uncaria tomentosa extract (PTI-00703) is alsoable to cause a significant (p<0.001) dissolution of preformed isletamyloid fibrils (ie. amylin) at all time points, with a 72%dissolution/inhibition observed as early as 2 hours of incubation.

FIG. 10 are black and white graphs demonstrating separation of Uncariatomentosa extract by high pressure liquid chromatography (HPLC) andinitial purification of amyloid inhibitory ingredients. Panel Arepresents HPLC monitored at 490 nm and eluted with a acetonitrile/watergradient, demonstrating that the Uncaria tomentosa extract containedmultiple ingredients that eluted off the column, with a broad peakobserved at 13-45 minutes, and a peak observed at 80 minutes. Panel Bdemonstrates a fraction at 26 minutes that was re-injected and asymmetrical peak was obtained indicating that the polydispersity of thepanel A chromatogram is not due to column artifact, but due to thepresence of individual components within the Uncaria tomentosa extract.In Panel C, 60 μl of 25 μM of pre-fibrillized Aβ 1-40 was incubated for2 hours in the presence or absence of 0.0005 OD units of fraction 26 andfraction 80. Fraction 26 (but not fraction 80) exhibited potent amyloidinhibitory activity causing an 85% dissolution/disruption of Alzheimer'sdisease amyloid within a 2-hour incubation period.

BEST MODE OF CARRYING OUT THE INVENTION

Turning now to the drawings, the invention will be described in apreferred embodiment by reference to the numerals of the drawing figureswherein like numbers indicate like parts.

Amyloid and Amyloidosis

Amyloid is a generic term referring to a group of diverse, but specificextracellular protein deposits which all have common morphologicalproperties, staining characteristics, and x-ray diffraction spectra.Regardless of the nature of the amyloid protein deposited all amyloidshave the following characteristics: 1) an amorphous appearance at thelight microscopic level and appear eosinophilic using hematoxylin andeosin stains; 2) all stain with Congo red and demonstrate a red/greenbirefringence as viewed under polarized light (Puchtler et al., J.Histochem. Cytochem. 10:355-364, 1962), 3) all contain a predominantbeta-pleated sheet secondary structure, and 4) ultrastructurally amyloidusually consist of non-branching fibrils of indefinite length and with adiameter of 7-10 nm.

Amyloid today is classified according to the specific amyloid proteindeposited. The amyloid diseases include, but are not limited to, theamyloid associated with Alzheimer's disease, Down's syndrome andHereditary cerebral hemorrhage with amyloidosis of the Dutch type(wherein the specific amyloid is referred to as beta-amyloid protein orAβ), the amyloid associated with chronic inflammation, various forms ofmalignancy and Familial Mediterranean Fever (wherein the specificamyloid is referred to as AA amyloid or inflammation-associatedamyloidosis), the amyloid associated with multiple myeloma and otherB-cell dyscrasias (wherein the specific amyloid is referred to as ALamyloid), the amyloid associated with type II diabetes (wherein thespecific amyloid is referred to as amylin or islet amyloid), the amyloidassociated with the prion diseases including Creutzfeldt-Jakob disease,Gerstmann-Straussler syndrome, kuru and animal scrapie (wherein thespecific amyloid is referred to as PrP amyloid), the amyloid associatedwith long-term hemodialysis and carpal tunnel syndrome (wherein thespecific amyloid is referred to as beta₂-microglobulin amyloid), theamyloid associated with senile cardiac amyloid and Familial AmyloidoticPolyneuropathy (wherein the specific amyloid is referred to asprealbumin or transthyretin amyloid), and the amyloid associated withendocrine tumors such as medullary carcinoma of the thyroid (wherein thespecific amyloid is referred to as variants of procalcitonin).

Although amyloid deposits in clinical conditions share common physicalproperties relating to the presence of a beta-pleated sheetconformation, it is now clear that many different chemical types existand additional ones are likely to be described in the future. It iscurrently thought that there are several common pathogenetic mechanismsthat may be operating in amyloidosis in general. In many cases, acirculating precursor protein may result from overproduction of eitherintact or aberrant molecules (ex. plasma cell dyscrasias), reduceddegradation or excretion (serum amyloid A in some secondary amyloidsyndromes and beta₂-microglobulin in long-term hemodialysis), or geneticabnormalities associated with variant proteins (ex. familial amyloidoticpolyneuropathy). Proteolysis of a larger protein precursor moleculeoccurs in many types of amyloidosis, resulting in the production oflower molecular weight fragments that polymerize and assume abeta-pleated sheet conformation as tissue deposits, usually in anextracellular location. What are the precise mechanisms involved, andthe aberrant causes leading to changes in proteolytic processing and/ortranslational modifications is not known in most amyloids.

Systemic amyloids which include the amyloid associated with chronicinflammation, various forms of malignancy and Familial MediterraneanFever (ie. AA amyloid or inflammation-associated amyloidosis) (Bensonand Cohen, Arth. Rheum. 22:36-42, 1979; Kamei et al, Acta Path. Jpn.32:123-133, 1982; McAdam et al, Lancet 2:572-573, 1975; Metaxas, KidneyInt. 20:676-685, 1981), and the amyloid associated with multiple myelomaand other B-cell dyscrasias (ie. AL amyloid) (Harada et al, J.Histochem. Cytochem. 19:1-15, 1971), as examples, are known to involveamyloid deposition in a variety of different organs and tissuesgenerally lying outside the central nervous system. Amyloid depositionin these diseases may occur, for example, in liver, heart, spleen,gastrointestinal tract, kidney, skin, and/or lungs (Johnson et al, N.Engl. J. Med. 321:513-518, 1989). For most of these amyloidoses, thereis no apparent cure or effective treatment and the consequences ofamyloid deposition can be detrimental to the patient. For example,amyloid deposition in kidney may lead to renal failure, whereas amyloiddeposition in heart may lead to heart failure. For these patients,amyloid accumulation in systemic organs leads to eventual deathgenerally within 3-5 years. Other amyloidoses may affect a single organor tissue such as observed with the Aβ amyloid deposits found in thebrains of patients with Alzheimer's disease and Down's syndrome: the PrPamyloid deposits found in the brains of patients with Creutzfeldt-Jakobdisease, Gerstmann-Straussler syndrome, and kuru; the islet amyloid(amylin) deposits found in the islets of Langerhans in the pancreas of90% of patients with type II diabetes (Johnson et al, N. Engl. J. Med.321:513-518, 1989; Lab. Invest. 66:522-535, 1992); thebeta₂-microglobulin amyloid deposits in the medial nerve leading tocarpal tunnel syndrome as observed in patients undergoing long-termhemodialysis (Geyjo et al, Biochem. Biophys. Res. Comm. 129:701-706,1985; Kidney Int. 30:385-390, 1986); the prealbumin/transthyretinamyloid observed in the hearts of patients with senile cardiac amyloid;and the prealbumin/transthyretin amyloid observed in peripheral nervesof patients who have Familial Amyloidotic Polyneuropathy (Skinner andCohen, Biochem. Biophys. Res. Comm. 99:1326-1332, 1981; Saraiva et al,J. Lab. Clin. Med. 102:590-603, 1983; J. Clin. Invest. 74:104-119, 1984;Tawara et al, J. Lab. Clin. Med. 98:811-822, 1989).

Alzheimer's Disease and the Aging Population

Alzheimer's disease is a leading cause of dementia in the elderly,affecting 5-10% of the population over the age of 65 years (A Guide toUnderstanding Alzheimer's Disease and Related Disorders, edited by Jorm,New York University Press, New York, 1987). In Alzheimer's disease, theparts of the brain essential for cognitive processes such as memory,attention, language, and reasoning degenerate, robbing victims of muchthat makes us human, including independence. In some inherited forms ofAlzheimer's disease, onset is in middle age, but more commonly, symptomsappear from the mid-60's onward. Alzheimer's disease today affects 4-5million Americans, with slightly more than half of these peoplereceiving care at home, while the others are in many different healthcare institutions. The prevalence of Alzheimer's disease and otherdementias doubles every 5 years beyond the age of 65, and recent studiesindicate that nearly 50% of all people age 85 and older have symptoms ofAlzheimer's disease (1997 Progress Report on Alzheimer's Disease,National Institute on Aging/National Institute of Healt). 13% (33million people) of the total population of the United States are age 65and older, and this % will climb to 20% by the year 2025 (1997 ProgressReport on Alzheimer's Disease, National Institute on Aging/NationalInstitute of Health).

Alzheimer's disease also puts a heavy economic burden on society aswell. A recent study estimated that the cost of caring for oneAlzheimer's disease patient with severe cognitive impairments at home orin a nursing home, is more than $47,000 per year (A Guide toUnderstanding Alzheimer's Disease and Related Disorders, edited by Jorm,New York University Press, New York, 1987). For a disease that can spanfrom 2 to 20 years, the overall cost of Alzheimer's disease to familiesand to society is staggering. The annual economic toll of Alzheimer'sdisease in the United States in terms of health care expenses and lostwages of both patients and their caregivers is estimated at $80 to $100billion (1997 Progress Report on Alzheimer's Disease, National Instituteon Aging/National Institute of Health).

Tacrine hydrochloride (“Cognex”), the first FDA approved drug forAlzheimer's disease is a acetylcholinesterase inhibitor (Cutler andSramek, N. Engl. J. Med. 328:808-810, 1993). However, this drug hasshowed limited success in the cognitive improvement in Alzheimer'sdisease patients and initially had major side effects such as livertoxicity. The second more recently FDA approved drug, donepezil (alsoknown as “Aricept”), which is also an acetylcholinesterase inhibitor, ismore effective than tacrine, by demonstrating slight cognitiveimprovement in Alzheimer's disease patients (Barner and Gray, Ann.Pharmacotherapy 32:70-77, 1998; Rogers and Friedhoff, Eur. Neuropsych.8:67-75, 1998), but is not believed to be a cure. Therefore, it is clearthat there is a need for more effective treatments for Alzheimer'sdisease patients.

Amyloid as a Therapeutic Target for Alzheimer's Disease

Alzheimer's disease is characterized by the deposition and accumulationof a 39-43 amino acid peptide termed the beta-amyloid protein, Aβ orβ/A4 (Glenner and Wong, Biochem. Biophys. Res. Comm. 120:885-890, 1984;Masters et al, Proc. Natl. Acad. Sci. USA 82:4245-4249, 1985; Husby etal, Bull WHO 71:105-108, 1993). Aβ is derived from larger precursorproteins termed beta-amyloid precursor proteins (or βPPs) of which thereare several alternatively spliced variants. The most abundant forms ofthe βPPs include proteins consisting of 695, 751 and 770 amino acids(Tanzi et al, Nature 331:528-530, 1988; Kitaguchi et al, Nature331:530-532, 1988; Ponte et al, Nature 331:525-527, 1988).

The small Aβ peptide is a major component which makes up the amyloiddeposits of “plaques” in the brains of patients with Alzheimer'sdisease. In addition, Alzheimer's disease is characterized by thepresence of numerous neurofibrillary “tangles”, consisting of pairedhelical filaments which abnormally accumulate in the neuronal cytoplasm(Grundke-Iqbal et al, Proc. Natl. Acad. Sci. USA 83:4913-4917, 1986;Kosik et al, Proc. Natl. Acad. Sci. USA 83:4044-4048, 1986; Lee et al,Science 251:675-678, 1991). The pathological hallmarks of Alzheimer'sdisease is therefore the presence of “plaques” and “tangles”, withamyloid being deposited in the central core of plaques. The other majortype of lesion found in the Alzheimer's disease brain is theaccumulation of amyloid in the walls of blood vessels, both within thebrain parenchyma and in the walls of meningeal vessels which lie outsidethe brain. The amyloid deposits localized to the walls of blood vesselsare referred to as cerebrovascular amyloid or congophilic angiopathy(Mandybur, J. Neuropath. Exp. Neurol. 45:79-90, 1986; Pardridge et al,J. Neurochem. 49:1394-1401, 1987).

For many years there has been an ongoing scientific debate as to theimportance of “amyloid” in Alzheimer's disease and whether the “plaques”and “tangles” characteristic of this disease, were a cause or merely theconsequences of the disease. Within the last few years, studies nowindicate that amyloid is indeed a causative factor for Alzheimer'sdisease and should not be regarded as merely an innocent bystander. TheAlzheimer's Aβ protein in cell culture has been shown to causedegeneration of nerve cells within short periods of time (Pike et al,Br. Res. 563:311-314, 1991; J. Neurochem. 64:253-265, 1995). Studiessuggest that it is the fibrillar structure (consisting of a predominantβ-pleated sheet secondary structure), characteristic of all amyloids,that is responsible for the neurotoxic effects. Aβ has also been foundto be neurotoxic in slice cultures of hippocampus (Harrigan et al,Neurobiol. Aging 16:779-789, 1995) and induces nerve cell death intransgenic mice (Games et al, Nature 373:523-527, 1995; Hsiao et al,Science 274:99-102, 1996). Injection of the Alzheimer's Aβ into ratbrain also causes memory impairment and neuronal dysfunction Flood etal, Proc. Natl. Acad. Sci. 88:3363-3366, 1991; Br. Res. 663:271-276,1994).

Probably, the most convincing evidence that Aβ amyloid is directlyinvolved in the pathogenesis of Alzheimer's disease comes from geneticstudies. It has been discovered that the production of Aβ can resultfrom mutations in the gene encoding, its precursor, beta-amyloidprecursor protein (Van Broeckhoven et al, Science 248:1120-1122, 1990;Murrell et al, Science 254:97-99, 1991; Haass et al, Nature Med.1:1291-1296, 1995). The identification of mutations in the beta-amyloidprecursor protein gene which causes early onset familial Alzheimer'sdisease is the strongest argumnent that amyloid is central to thepathogenetic process underlying this disease. Four reporteddisease-causing mutations have now been discovered which demonstrate theimportance of Aβ in causing familial Alzheimer's disease (reviewed inHardy, Nature Genet. 1:233-234, 1992). All of these studies suggest thatproviding a drug to reduce, eliminate or prevent fibrillar Aβ formation,deposition, accumulation and/or persistence in the brains of humanpatients is believed to serve as an effective therapeutic.

Uncaria tomentosa

The plant Uncaria tomentosa, also known as “Uña de Gato” (in Spanish) or“Cat's claw” (in English) refers to a woody vine which grows within thePeruvian Amazon rain forest. This slow growing vine takes 20 years toreach maturity, and can grow over 100 feet in length as it attaches andwraps itself around the native trees. It is found abundantly in thefoothills, at elevations of two to eight thousand feet. The vine isreferred to as “Cat's claw” because of its distinctive curved claw-likethorns which project from the base of its leaves. The native Indiantribes traditionally have boiled the inner bark and root of the herb tomake a tea decoction and regard Uncaria tomentosa as a sacred medicinalplant. The highly effective properties contained within the inner barkof this plant are believed to have a profound and positive influence onthe body, although scientific medical data is generally lacking on itspotential benefits in humans. The alkaloids and phytochemicals in theinner bark of Uncaria tomentosa are almost identical to those found inthe root, and harvesting this way preserves the plant and provides forthe future of the rainforest.

Some of the active substances present in Uncaria tomentosa are alkaloids(see Keplinger patents referred to above), which occur in the plant andits watery extract as a complex bound to tannins. In this form, onlylittle of them can be activated. The complexes get split by the acidmilieu of the stomach; the alkaloids get transformed into theirhydrochloride form, and in this way, get well absorbed. A darker Uncariatomentosa extract means more tannin is present and beneficial alkaloidsare locked up with the tannins, which have formed a non-bioavailable andpoorly absorbed complex. A light golden color of Uncaria tomentosasuggests that there is less tannins, and more alkaloids available in theextract.

Besides the presence of alkaloids, Uncaria tomentosa is believed to alsocontain other beneficial phytochemicals including quinovic acidglycosides, proanthocyanidins, polyphenols, triterpines and the plantsterols beta-sitosterol, stigmasterol and campesterol (P Steinberg“Uncaria tomentosa (Cat's Claw) a wondrous herb from the Peruvian rainforest”, Townsend Letter for Doctors, May, 1994; P. Steinberg, “Cat'sclaw update-Uncaria tomentosa: that wondrous herb from the Peruvian rainforest”, Townstead Letter for Doctors, August/September 1995, “Cat'sClaw Miracle Herb from the Rain Forest of Peru”, Woodland Publ. Inc.,Pleasant Grove, Vt., USA).

Uncaria tomentosa is one of the most important plants in the SouthAmerican Peruvian rainforest. A number of oxindole alkaloids havealready been isolated from the inner bark of this plant. Two U.S.patents (U.S. Pat. No. 4,844,901 and U.S. Pat. No. 4,940,725 byKeplinger) describe the isolation and use of six oxindole alkaloids fromUncaria tomentosa, which are believed to be “suitable for theunspecified stimulation of the immunologic system”. These oxindolealkaloids are believed to provide a general boost to the immune systemas well as have a profound effect on the ability of white blood cellsand macrophages to phagocytize harmful microorganisms and foreignmatter. The most immunologically active alkaloid appears to bealloisopteropodine, isomer A, a pentacyclic oxindole alkaloid (U.S. Pat.No. 4,940,725).

Although some health care providers have suggested that Uncariatomentosa may be used to treat a variety of ailments, nowhere has therebeen any use, or suggestion of use, of this compound for the treatmentof amyloid formation, deposition, accumulation and/or persistence, suchas that which occurs in the amyloidoses, including Alzheimer's disease.The present invention clearly demonstrates the effectiveness of Uncariatomentosa and its extracts and derivatives obtained from differentcommercial sources for the 1) inhibition of Alzheimer's Aβ amyloidfibril formation (important for patients in early to mid-stageAlzheimer's disease), 2) inhibition of Alzheimer's amyloid fibril growth(important for patients in early to mid-stage Alzheimer's disease), 3)inhibition of Alzheimer's amyloid-PG/GAG interactions (important forpatients in all stages of Alzheimer's disease) and 4) causing thedissolution/disruption of preformed Alzheimer's disease amyloid fibrils.In addition, the present invention demonstrates that Uncaria tomentosais effective in causing the dissolution of islet amyloid fibrils (ie.amylin) and therefore may serve as an effective treatment for ˜90% oftype II diabetic patients who have islet amyloid accumulation in thepancreas.

EXAMPLES

The following examples are put forth so as to provide those withordinary skill in the art with the disclosure and description of theidentification and use of commercially available Uncaria tomentosa toinhibit amyloid fibril formation, inhibit amyloid fibril growth, inhibitamyloid-PG/GAG interactions, and cause dissolution/disruption ofpreformed amyloid fibril. However, it should not be construed that theinvention is limited to these specific examples.

Example 1 Glucosamine (Sulfate Salt) Containing Uncaria tomentosa is aPotent Inhibitor of Alzheimer's Aβ (1-40) Amyloid Fibril Formation

A previously described method of measuring amyloid fibril formationutilizing Thioflavin T fluorometry (H Naiki et al, Lab. Invest.65:104-110, 1991; H Levine III, Protein Sci. 2:404-410, 1993; H LevineIII, Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, 1995; H Naiki and K.Nakakuki, Lab. Invest. 74:374-383, 1996) was employed initially toidentify potential therapeutic compounds capable of inhibitingAlzheimer's Aβ amyloid fibril formation. Using this sensitive assay, anydecreases or increases in fluorescence was previously shown to correlatewith a decrease or increase in the amount of amyloid fibrils (H Naiki etal, Lab. Invest. 65:104-110, 1991; H Levine III, Protein Sci. 2:404-410,1993; H Levine III, Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, 1995; HNaiki and K. Nakakuki, Lab. Invest. 74:374-383, 1996), allowing one todetermine the identification and extent of potential inhibitors and/orenhancers of amyloid fibril formation.

Our screening studies first suggested the detection of a potentAlzheimer's disease amyloid inhibitory agent which was present as anadded ingredient in one of the compounds that we initially tested. Inone study, the effects of various compounds on Alzheimer's Aβ (1-40)fibril formation was assessed by Thioflavin T fluorometry. Thioflavin Tis known to bind to fibrillar amyloid proteins, and an increase influorescence correlates with an increase in amyloid fibril formation,whereas a decrease in fluorescence correlates with a decrease in amyloidfibril formation. The Alzheimer's Aβ protein (1-40) when incubated at37° C. tends to spontaneously form amyloid fibrils which increase inquantity over time. In this study, we tested for compounds which had thepotential to inhibit the Alzheimer's amyloid Aβ protein from formingfibril over a 1 week period. Thus, compounds identified have the abilityto inhibit Alzheimer's amyloid fibril formation. For these studies, 25μM of Aβ (1-40) (Bachem Inc., Torrance, Calif., USA; Lot #WM365) wasincubated in microcentrifuge tubes at 37° C. for 1 week (in triplicate),either alone, or in the presence of 1.25 mM (ie. 1:50 M ratio of Aβ:testcompound) (except PTI-00700 which was isolated and used as describedbelow) of various compounds in 150 mM Tris HCl, 10 mM NaCl, pH 7.0(TBS). The compounds tested included PTI-07499 (mannose pentasulfate,potassium salt), PTI-20049 (methyl alpha-D-glucopyranoside2,3,4,6-tetrasulfate, potassium salt), PTI-20814 (methylalpha-D-mannopyranoside 2,3,4,6-tetrasulfate, potassium salt), PTI-70936(sucrose heptasulfate, potassium salt), PTI-70946 (sucrose hexasulfate,potassium salt), PTI-70011 (sucrose octasulfate, potassium salt)PTI-00800 (glucosamine, sulfate salt, from Enzymatic Therapy, Green Bay,Wis. and commercially known as “glucosamine sulfate”), PTI-00900(glucosamine, sulfate salt, from Jarrows Formulas, Los Angeles, Calif.and commercially known as “glucosamine sulfate 500”,) and PTI-00700,(Glucosamine, sulfate salt, with Uncaria tomentosa). PTI-00700 wasderived from preservative free capsules containing 400 mg blend ofglucosamine (sulfate salt) and 50 mg of Uncaria tomentosa's inner bark.For these studies, the powder within one capsule of PTI-00700 wasextracted in 5 ml of distilled water and pelleted by gravity. Thesoluble fraction was then obtained and used in these studies at a finaldilution of 1:227 in Tris-buffered saline (TBS) (comparable to theconcentration of other compounds tested in terms of glucosamine).

To assess the effects of each compound on Aβ (1-40) fibril formation, 50μl aliquots were taken from each tube for analysis at 1 hr, 1 day, 3days, and 1 week. For each determination described above, following eachincubation period, 50 μl of Aβ +/− test compounds were added to 1.2 mlof 100 μM Thioflavin T (Sigma Chemical Co., St. Louis, Mo.) in 50 mMNaPO₄ (pH 6.0). Studies indicated that increasing concentrations of Aβgave a proportional increase in fluorescence in the presence of 100 μMThioflavin T, ruling out the presence of any disproportionate innerfilter effects in these studies. Fluorescence emission at 482 nm wasmeasured on a Turner instrument-model 450 fluorometer at an excitationwavelength of 450 nm. For each determination, the fluorometer wascalibrated by zeroing in the presence of the Thioflavin T reagent alone,and by setting the 50 ng/ml riboflavin (Sigma Chemical Co., St. Louis,Mo.) in the Thioflavin T reagent to 1800 fluorescence units. Allfluorescence determinations were based on these references and anyfluorescence given off by any of the compounds in the presence of theThioflavin T reagent was always subtracted from all pertinent readings.

For all fibrillogenesis studies utilizing Thioflavin T fluorometry, asdisclosed herein, comparisons of amyloid protein in the presence orabsence of test compounds were based on paired Student's t tests withdata shown as mean+/−standard deviation. Significance was reported atthe 95% (p<0.05), 99% (p<0.01) and 99.999% (p<0.001) confidence levels.

As shown in FIG. 1, the effects of these various test compounds onAlzheimer's Aβ (1-40) amyloid fibril formation was evaluated over a1-week incubation period. Freshly suspended Aβ (1-40) alone, following a1-hour incubation at 37° C., demonstrated an initial fluorescence of75+/−9 fluorescence units. During the 1-week incubation period, therewas a gradual increase in the fluorescence of Aβ (1-40) alone,increasing 6.1-fold from 1 hour to 1 week, with a peak fluorescence of459+/−18 fluorescence units observed at 1 week (FIG. 1), consistent withprevious studies (Castillo et al, J. Neurochem. 69:2452-2465, 1997). Ofall the compounds tested, only glucosamine (sulfate salt) containingUncaria tomentosa (ie. PTI-00700) significantly inhibited Aβ (1-40)amyloid fibril formation. Glucosamine (sulfate salt) derived from twodifferent sources (ie. PTI-00800 and PTI-00900) which did not containUncaria tomentosa did not significantly inhibit Aβ (1-40) amyloid fibrilformation (FIG. 1). This indicated that the active amyloid inhibitoryagent was most likely Uncaria tomentosa. The significant inhibition ofAβ amyloid fibril formation by glucosamine (sulfate salt) containingUncaria tomentosa (ie. PTI-00700) was detected as early as 1 hour ofincubation. Significant inhibition (p<0.001) by glucosamine (sulfatesalt) containing Uncaria tomentosa on Aβ amyloid fibril formation wasobserved at all time points including 1 hour, 1 day, 3 days and 1 week.By 1 week, glucosamine (sulfate salt) containing Uncaria tomentosa waseffective in significantly (p<0.001) inhibiting amyloid fibril formationby 78%. This initial data indicated that glucosamine (sulfate salt)containing Uncaria tomentosa was a potent inhibitor of Alzheimer'samyloid fibril formation.

Example 2 Uncaria tomentosa is the Active Agent and a Potent Inhibitorof Alzheimer's Aβ(1-40) Amyloid Fibril Formation

The next studies were designed to reproduce some of the data initiallyacquired and to determine if the active agent which inhibited Aβ amyloidfibril formation was in fact Uncaria tomentosa. In these studies, theeffects of various compounds on Alzheimer's Aβ (1-40) fibrillogenesiswere again assessed using Thioflavin T fluorometry. For these studies,25 μM of Aβ (1-40)(Bachem Inc., Torrance, Calif., USA; Lot #WM365) wasincubated in microcentrifuge tubes at 37° C. for 1 week (in triplicate),either alone, or in the presence of 1.25 mM (ie. 1:50 M ratio of Aβ:testcompound) of various compounds (except PTI-00700, PTI-00701 andPTI-00703 which were isolated and used as described below) in 150 mMTris HCl, 10 mM NaCl, pH 7.0 (TBS). The compounds tested includedglucosamine (sulfate salt) containing Uncaria tomentosa (PTI-00700),glucosamine (sulfate salt) containing Uncaria tomentosa which wasfiltered through a filter containing a 30 kilodalton cutoff(PTI-00700<30 kDa), glucosamine (hydrochloride salt) containing Uncariatomentosa (PTI-00701), pure glucosamine (PTI-00712; molecularweight=216; obtained from the Sigma Chemical Company, St. Louis, Mo.,USA), pure galactosamine (PTI-00713; molecular weight=216; obtained fromthe Sigma Chemical Company, St. Louis, Mo., USA), sodium sulfate(PTI-00725; molecular weight=142; obtained from the Sigma ChemicalCompany, St. Louis, Mo., USA), and Uncaria tomentosa (PTI-00703;obtained from a commercial source). For these studies, the powder withinone gelatin-coated capsule of glucosamine sulfate containing Uncariatomentosa (PTI-00700) was extracted in 5 ml of distilled water and usedfor testing as described in Example 1. The powder within onegelatin-coated capsule of glucosamine (hydrochloride salt) containingUncaria tomentosa (PTI-00701) was extracted in 5 ml of distilled waterand used at a final dilution of 1:40 in TBS (which represented the totalextract derived from 250 μg of Uncaria tomentosa per ml), whereas thepowder within one gelatin-coated capsule of Uncaria tomentosa(PTI-00703) was extracted in 5 ml of distilled water and used at a finaldilution of 1:250 in TBS (which represented the total extract derivedfrom 350 kg of Uncaria tomentosa per ml).

To assess the effects of each compound on Alzheimer's Aβ (1-40) fibrilformation, 50 μl aliquots were taken from each tube for analysis at 1hr, 1 day, 3 days, and 1 week using Thioflavin T fluorometry asdescribed above. As shown in FIG. 2, the effects of these various testcompounds on Aβ (1-40) amyloid fibril formation was evaluated over a1-week incubation period. Freshly suspended Aβ (1-40) alone, following a1-hour incubation at 37° C., demonstrated an initial fluorescence of113+/−7 fluorescence units. During the 1-week incubation period, therewas a gradual increase in the fluorescence of Aβ (1-40) alone,increasing 2.2-fold from 1 hour to 1 week, with a peak fluorescence of250+/−50 fluorescence units observed at 1 week. Glucosamine (sulfatesalt) containing Uncaria tomentosa (PTI-00700), and glucosamine (sulfatesalt) containing Uncaria tomentosa which was filtered through a filtercontaining a 30 kilodalton cutoff (PTI-00700<30 kDa) were both potentinhibitors of Aβ amyloid fibril formation causing a 68% and 72%inhibition at 1 week, respectively (FIG. 2). An even more potentinhibition of amyloid fibril formation was observed with glucosamine(hydrochloride salt) containing Uncaria tomentosa (PTI-00701) causing a90% inhibition of Aβ amyloid fibril formation by 1 week. Each of thesepotent compounds significantly inhibited amyloid fibril formation asearly as 1 hour following incubation. The active ingredient which wasdeemed to cause this potent inhibitory effect on amyloid fibrilformation was Uncaria tomentosa contained within these commercialpreparations. This was due to the fact that glucosamine (PTI-00712)which did not contain Uncaria tomentosa had no inhibitory effect onamyloid fibril formation whatsoever. In addition, pure Uncaria tomentosa(PTI-00703) caused a similar inhibitory effect (73% inhibition at 1week; and a 93% inhibition at 1 hour) on amyloid fibril formation tothat observed with glucosamine (sulfate salt) containing Uncariatomentosa. These data indicated that the active ingredient which was apotent inhibitor of Alzheimer's disease amyloid fibril formation wasUncaria tomentosa.

Example 3 Glucosamine (Sulfate Salt) Containing Uncaria tomentosa(PTI-00700) Inhibits Alzheimer's Amyloid Fibril Growth

In Alzheimer's disease and other amyloidoses, amyloid fibril growth isbelieved to involve amyloid protein self-interactions (ie. Aβ-Aβinteractions). Any potential effective therapeutic agent for amyloiddeposition, accumulation and/or persistence should also be capable ofcausing an inhibition of amyloid protein self-interactions. This isimportant for preventing any new amyloid fibril formation when treatingAlzheimer's disease patients at early stages of the disease. ELISAmethodologies (i.e. solid phase binding assays) were therefore used toidentify compounds which were capable of inhibiting Aβ-Aβ interactions(i.e. Alzheimer's amyloid fibril growth).

Aβ (1-40) was first labelled with biotin according to the followingprotocol. 1 mg of Aβ (1-40) (Bachem Inc., Torrance, Calif., USA; Lot#WL934) was dissolved in 200 μl of PBS (pH 8.0) and incubated for 1 weekat 37° C. The fibrillar Aβ solution was then added to 0.2 mg of abiotinylation agent[(sulfosuccinimidyl-6-(biotinamido)hexanoate)](sulfo-NHS-LC-Biotin) andincubated for 45 minutes at room temperature (according to themanufacturer's protocol; Pierce). To remove excess sulfo-NHS-LC-Biotinnot incorporated into Aβ, 25 μl of 3M sodium acetate and 1 ml of ethanolwere added to the solution, vortexed and then centrifuged at 14,000×gfor 20 minutes. The supernatant was then discarded and the pellet wasresuspended in 200 μl of distilled water, and reprecipitated withethanol containing 2.5% of 3M sodium acetate. The centrifugation steps(described above) were then repeated. The pellet which containedfibrillized Aβ which was biotinylated (at the non self-interactingregion of Aβ) was then resuspended in 1 ml of distilled deionized water.The amount of biotin incorporated was then determined using the HABA(2-(4′-hydroxyazo-benzene)benzoic acid) method (according to themanufacturer's protocol; Pierce).

2 μg of unlabelled Aβ in 40 μl of Tris-buffered saline containing 100 mMTris-HCl, 50 mM NaCl, 3 mM NaN₃, pH 7.0 (TBS) was allowed to bindovernight at 4° C. to microtiter wells (Nunc plates, Maxisorb). The nextday all of the microtiter wells were blocked for 2 hours by incubatingwith 300 μl of TBS with 0.05% Tween-20 (TTBS) plus 2% bovine serumalbumin (BSA) (obtained from the Sigma Chemical Company, St. Louis, Mo.,USA). Then, 100 μl of biotinylated Aβ 1-40 in TTBS, in the presence orabsence of 1.25 mM of test compounds (described below) were placed inwells (in triplicate) containing substrate bound unlabelled Aβ or blank,and allowed to bind overnight at 4° C. The next day, the wells wererinsed 3 times with TTBS, and then probed for 2 hours with 100 μl ofstreptavidin-peroxidase or anti-biotinperoxidase (1:500 dilution of a 2μg/ml solution) (Sigma Chemical Co., St. Louis, Mo.) in TTBS containing0.1% BSA. The wells were then rinsed 3 times with TTBS and 100 μl of asubstrate solution (OPD-Sigma Fast from Sigma Chemical Co., St. Louis,Mo.) was added to each well and allowed to develop for 5 minutes oruntil a significant color change was observed. The reaction was stoppedwith 50 μl of 4N H₂SO₄ and read on a Model 450 microplate reader(Biorad, Hercules, Calif., USA) at 490 nm.

The compounds tested included sucrose octasulfate (PTI-70011), sucrosehexasulfate (potassium salt) (PTI-70946), sucrose heptasulfate(potassium salt) (PTI-70936), methyl alpha-D-mannopyranoside2,3,4,6-tetrasulfate (potassium salt) (PTI-20814), methylalpha-D-glucopyranoside 2,3,4,6-tetrasulfate (potassium salt)(PTI-20049), glucosamine (sulfate salt) (Enzymatic Therapy, Green Bay,Wis.) (PTI-00800), glucosamine (sulfate salt from Jarrows Formulas, LosAngeles, Calif., commercially known as “glucosamine sulfate 500”)(PTI-00900), glucosamine (sulfate salt) containing Uncaria tomentosa(PTI-00700), heparin (PTI-H98546), chondroitin-4-sulfate (PTI-C45770),and dermatan sulfate (PTI-D58901). Glucosamine (sulfate salt) containingUncaria tomentosa (PTI-00700) was isolated and used at a dilution of1:227 in Tris-buffered saline containing 0.05% Tween-20 (TTBS), asdescribed in Example 2.

As shown in FIG. 3, only glucosamine (sulfate salt) containing Uncariatomentosa (PTI-00700) was effective in causing a significant (p<0.001)70% reduction in Aβ-Aβ interactions. The active ingredient which causedthis inhibition was Uncaria tomentosa, since pure glucosamine (sulfatesalt) obtained from two different sources (ie. PTI-00800 and PTI-00900)had no inhibitory effects on amyloid fibril growth whatsoever (FIG. 3).These data demonstrated that glucosamine (sulfate salt) containingUncaria tomentosa was an effective inhibitor of Aβ-Aβ interactions, andthat the active ingredient which was a potent inhibitor of Alzheimer'sdisease amyloid fibril growth was Uncaria tomentosa.

Example 4 Glucosamine (Sulfate Salt) Containing Uncaria tomentosaInhibit Aβ-Proteoglycan/Glycosaminoglycan Interactions in aDose-Dependent Manner

One study was implemented to determine whether glucosamine (sulfatesalt) containing Uncaria tomentosa was an effective inhibitor ofAβ-proteoglycan/glycosaminoglycan (PG/GAG) interactions. Since PGs/GAGshave been found to accumulate in amyloid deposits and are believed toprevent the body's natural ability to remove unwanted “amyloid”(reviewed in Snow and Wight, Neurobiology Aging 10:481-497, 1989), aninhibitor of Aβ-PG/GAG interactions is a desirable additional target foran amyloid therapeutic. In this study a solid phase binding immunoassaywas utilized to determine whether glucosamine (sulfate salt) containingUncaria tomentosa (PTI-00700) was an effective inhibitor of Aβ-PG/GAGinteractions and whether this inhibition occurred in a dose-dependentmanner.

12 μg of perlecan (isolated from the Engelbreth-Holm-Swarm sarcoma)(Castillo et al, J. Biochemistry 120:433-444, 1996), heparin (molecularweight=5 kDa; obtained from the Sigma Chemical Company, St. Louis, Mo.,USA) or heparan sulfate (molecular weight=˜70 kDa; obtained fromSeikagaku America, Rockville, Md.) in 80 μl of Tris-buffered salinecontaining 100 mM Tris-HCl, 50 mM NaCl, 3 mM NaN₃, pH 9.0 (TBS) wasallowed to bind overnight at 4° C. to microtiter wells (Nunc plates,Maxisorb). The next day all of the microtiter wells were blocked for 2hours by incubating with 300 μl of TBS with 0.05% Tween-20 (TTBS) plus1% bovine serum albumin (BSA) (obtained from the Sigma Chemical Company,St. Louis, Mo., USA). Then, 100 μl of Aβ 1-40 (5 μM) (Bachem Inc.,Torrance, Calif., USA; Lot #WM365) in TTBS containing 0.05% albumin inthe presence or absence of 5 μl of glucosamine (sulfate salt) containingUncaria tomentosa (PTI-00700) were placed in wells (in triplicate)containing substrate bound PG/GAG or blank, and allowed to bindovernight at 4° C. For the study, a water extract of glucosamine(sulfate salt) containing Uncaria tomentosa (i.e. PTI-00700) was derivedby taking the powder from 1 gelatin-coated capsule/pill (which contains50 mg of Uncaria tomentosa) and extracting two times with 2.5 ml ofdouble distilled water and then pooling the two water extracts together(referred to as the “PTI-00700 solution”). The PTI-00700 solution wasthen used undiluted (which represented 1/1,000th of a single pill), ordiluted at ratios of 1:3 (i.e. 1/3,000th of a single pill), 1:9 (i.e.1/9,000th of a single pill) or 1:27 ( 1/27,000th of a single pill), withdistilled water. The next day, the wells were rinsed once with TTBS, andthen probed for 45 minutes with 100 μl of anti-6E10 (Senetek, MarylandHeights, Mo.) (which recognizes Aβ 1-17) diluted 1:1000 with TTBS. Thiswas followed by rinsing once with TTBS and probed for 45 minutes withbiotinylated goat-anti mouse (diluted 1:1000) containingstreptavidin-peroxidase or anti-biotinperoxidase (1:500 dilution of a 2μg/ml solution)(Sigma Chemical Co., St. Louis, Mo.) in TTBS containing0.1% BSA. The wells were then rinsed 3 times with TTBS and 100 μl of asubstrate solution (OPD-Sigma Fast from Sigma Chemical Co., St. Louis,Mo.) was added to each well and allowed to develop for 5 minutes oruntil a significant color change was observed. The reaction was stoppedwith 50 μl of 4N H₂SO₄ and read on a Model 450 microplate reader(Biorad, Hercules, Calif., USA) at 490 nm.

As shown in FIG. 4, undiluted glucosamine (sulfate salt) containingUncaria tomentosa (PTI-00700) (which represented 1/1,000th of a singlepill) was very effective (by 64%) in inhibition of Aβ-heparin/heparansulfate interactions. A significant (p<0.001) 49% inhibition was alsoobserved with a 1:3 dilution (i.e. 1/3,000th of a single pill) ofPTI-00700, whereas a 1:9 dilution ( 1/19,000th of a single pill) ofPTI-00700 still caused a significant (p<0.01) 35% inhibition. A 1:27dilution (i.e. 1/27,000th of a single pill) of PTI-00700 was found notto cause a significant inhibition of Aβ-heparin/heparan sulfate binding.These data demonstrated that glucosamine (sulfate salt) containingUncaria tomentosa was also capable of inhibiting Aβ-PG/GAG interactionsin a dose-dependent manner.

Example 5 Uncaria tomentosa Causes a Dissolution of Pre-FormedAlzheimer's Disease Amyloid Fibrils in a Dose-Dependent Manner andWithin a 2-Hour Period

One study was implemented to determine whether a relatively pure Uncariatomentosa extract was capable of causing a “dissolution” or “disruption”of preformed Alzheimer's disease amyloid fibrils. This type of activitywould be important for any potential anti-amyloid drug which can be usedin patients who already have substantial amyloid deposition in organsand/or tissues. For example, Alzheimer's disease patients in mid-to latestage disease have abundant amyloid deposits in their brains as part ofboth neuritic plaques and cerebrovascular amyloid deposits. A naturaltherapeutic agent capable of causing dissolution of pre-existing amyloidwould be advantageous for use in these patients who are at latter stagesof the disease process.

For this study, 1 mg of Aβ (1-40) (Bachem Inc., Torrance, Calif., USA;Lot #WM365) was dissolved in 1.0 ml of double distilled water (1 mg/mlsolution) and then incubated at 37° C. for 1 week to cause abundantAlzheimer's amyloid fibril formation. 6 μl (25 μM) of fibrillized Aβ wasthen incubated for 2 hours at 37° C., in the presence or absence of 1.5μl of Uncaria tomentosa (PTI-00703) (described below) dissolved in 37.5μl of double distilled water, and 15 μl containing 150 mM Tris HCl, 10mM NaCl, pH 7.0. Following a 2 hour incubation, 50 μl aliquots wereadded to 1.2 ml of 100 μM Thioflavin T (Sigma Chemical Co., St. Louis,Mo.) in 50 mM NaPO₄ (pH 6.0) for fluorometry readings as described inExample 1 above.

For this study, the compounds tested included a water extract of Uncariatomentosa which was derived by taking the powder from 10 gelatin-coatedcapsules of Uncaria tomentosa (which contain ˜350 mg of Uncariatomentosa per capsule) and extracting two times with 25 ml of doubledistilled water, and then pooling the two water extracts together(referred to as “Uncaria tomentosa solution”). The Uncaria tomentosasolution was then used either undiluted (which represents 1/3,333th of asingle pill), or further diluted in distilled water at ratios of 1:3(i.e. 1/10,000th of a single pill), 1:9 (i.e. 1/30,000th of a singlepill) or 1:27 ( 1/90,000th of a single pill).

As shown in FIG. 4, undiluted (i.e. 1/3,333th of a single pill) Uncariatomentosa (PTI-00703) was extremely effective, and caused a 70%dissolution of pre-formed Alzheimer's Aβ amyloid fibrils within the2-hour incubation period. A significant (p<0.001) 63% dissolution ofpre-formed Alzheimer's Aβ amyloid fibrils was also observed with a 1:3;dilution (i.e. 1/10,000th of a single pill) of an Uncaria tomentosasolution, whereas a 1:9 dilution (i.e. 1/30,000th of a single pill) ofan Uncaria tomentosa solution still caused a significant (p<0.01) 60%dissolution. On the other hand, a 1:27 dilution (i.e. 1/90,000th of asingle pill) of an Uncaria tomentosa solution did not cause asignificant dissolution of pre-formed Aβ amyloid fibrils. These datademonstrated that Uncaria tomentosa causes dissolution of pre-formedAlzheimer's disease amyloid fibrils in a dose-dependent manner.Confirmation of the “dissolution effect” of Uncaria tomentosa onAlzheimer's disease amyloid fibrils was demonstrated by Congo redstaining assays, whereby a marked reduction of congophilia (i.e.red/green birefringence when viewed under polarized light, and whichrepresents a dissolution/disruption of the amyloid fibrillar structure)was observed when Aβ amyloid fibrils were treated with Uncaria tomentosafor 2 hours (not shown).

Example 6 Uncaria tomentosa in Liquid Form and from Another CommercialSource also Causes Dissolution of Pre-Formed Alzheimer's Disease AmyloidFibrils

The next study determined whether Uncaria tomentosa derived from anothercommercial source (referred to as PTI-00703-2) was also effective incausing dissolution/disruption of pre-formed Alzheimer's disease Aβ(1-40) amyloid fibrils. This study also addressed whether an extractderived from Uncaria tomentosa in liquid form (commercially availablefor oral consumption by humans) caused a similar dissolution ofpre-formed Aβ amyloid fibrils as observed using Uncaria tomentosaderived from gelatin-coated capsule form. For this study, the protocoldescribed in example 5 as described above was used. Briefly, 1 mg of Aβ(1-40) (Bachem Inc., Torrance, Calif., USA; Lot #WM365) was dissolved in1.0 ml of double distilled water (1 mg/ml solution) and then incubatedat 37° C. for 1 week. 6 μl (25 μM) of fibrillized Aβ was then incubatedfor 2 hours at 37° C., in the presence or absence of 1.5 μl ofliquid-derived Uncaria tomentosa (PTI-00703-2) dissolved in 37.5 μl ofdouble distilled water, and 15 μl containing 150 mM Tris HCl, 10 mMNaCl, pH 7.0. Following a 2 hour incubation, 50 μl aliquots were addedto 1.2 ml of 100 μM Thioflavin T (Sigma Chemical Co., St. Louis, Mo.) in50 mM NaPO₄ (pH 6.0) for fluorometry readings as described in example 1.

As shown in FIG. 6, liquid-derived Uncaria tomentosa was extremelyeffective in causing a dissolution/disruption of pre-formed Aβ amyloidfibrils. A significant (p<0.001) 70% dissolution of pre-formed Aβamyloid fibrils was observed using liquid-derived Uncaria tomentosawithin a 2-hour incubation period. This study demonstrated that Uncariatomentosa was an effective dissolver of pre-formed Alzheimer's diseaseamyloid fibrils regardless of the source of Uncaria tomentosa, andregardless of whether the Uncaria tomentosa used was in solid (ie.capsule) or liquid form.

Example 7 Dose-Dependent Dissolution of Pre-Formed Alzheimer's DiseaseAmyloid Fibrils by Uncaria tomentosa Extract Obtained from a ThirdCommercial Source

The next study determined whether Uncaria tomentosa obtained from yetanother commercial source was also effective in causingdissolution/disruption of pre-formed Alzheimer's disease amyloidfibrils. For this study, Uncaria tomentosa was obtained from the powderwithin gelatin-coated capsules from a third commercial source (referredto as PTI-00703-R) and used as described below. For this study, a singlegelatin-coated capsule containing pure Uncaria tomentosa was opened andthe brown powder content was extracted with 1 ml of propanol followed bycentrifugation (14,000×g for 15 minutes). 0.1 μl of the propanol extractwas measured at 490 nm and found to demonstrate 0.0004 OD units. Thefibril dissolution assay was used as described in example 5 using 0.1 μl(i.e. 1 μl was diluted with double distilled water at a 1:10 dilutionand 1 μl was used), 1 μl, 2 μl and 4 μl of the PTI-00703-R extract.These amounts represented 1/10,000th, 1/1000th, 1/500th, and 1/250th ofthe total extract from a single pill, respectively.

As shown in FIG. 7, Uncaria tomentosa obtained from a singlegelatin-coated capsule or pill caused a dose-dependentdissolution/disruption of Alzheimer's Aβ amyloid fibrils and within a2-hour incubation period. A 1/10,000th portion obtained from a singlecapsule caused a significant (p<0.001) 58% dissolution, whereas a1/1,000 portion obtained from a single capsule caused a significant(p<0.001) 81% dissolution. A 1/500 portion from a single capsule causeda significant (p<0.001) 93% dissolution, whereas a 1/250th portion froma single pill caused a significant (p<0.001) 97% dissolution. This studydemonstrated that Uncaria tomentosa obtained from yet another source wasa potent agent causing dose-dependent dissolution of pre-formedAlzheimer's disease amyloid fibrils. In addition, the diluted contentsfrom a single gelatin-coated capsule/pill of Uncaria tomentosa (which iscurrently orally consumed by humans) was still extremely effective incausing a dissolution/disruption of Alzheimer's disease pre-formedamyloid fibrils.

Example 8 Uncaria tomentosa Extract Causes a Dissolution of Aβ (1-42)Alzheimer's Amyloid Fibrils

The amyloid fibrils of Alzheimer's disease primarily consist of Aβ in aform containing residues 1-40 or 1-42. The longer variant of Aβ containstwo hydrophobic residues which cause substantial fibril formation almostimmediately (Castillo et al, J. Neurochem. 69:2452-2465, 1997). Aβ 1-42is also believed to be the predominant form of Aβ existing inAlzheimer's amyloid plaques, whereas Aβ 1-40 is believed to be thepredominant form of Aβ existing in Alzheimer's cerebrovascular amyloiddeposits (Tamaoka et al, Br. Res. 679:151-156, 1995; Biochem. Biophys.Res. Comm. 205:834-842, 1994). The next study was therefore implementedto determine whether Uncaria tomentosa also causesdissolution/disruption of pre-formed Aβ (1-42) amyloid fibrils andwhether this effect was long-lasting.

For this study, the method of Thioflavin T fluorometry as described inexample 5 was used. Briefly, 30 μl of 250 μM of Aβ (1-42) (BachemBiosciences, King of Prussia, Pa., USA; Lot #508780) was mixed with 7.5μl of a Uncaria tomentosa stock solution (as described below), 75 μl of4×TBS and 187.5 μl of double distilled water (pH 7.0), and incubated inmicrocentrifuge tubes at 37° C. for 4 days (in triplicate), eitheralone, or in the presence of Uncaria tomentosa. The water extract ofUncaria tomentosa (PTI-00703) was derived by taking the powder contentsfrom 10 gelatin-coated capsules of Uncaria tomentosa and extracting twotimes with 25 ml of double distilled water. The extract was then diluted1:250 in double distilled water (1 ml of stock solution represented thetotal extract derived from 350 μg of Uncaria tomentosa) to generate anUncaria tomentosa stock solution.

As shown in FIG. 8, freshly suspended Alzheimer's Aβ (1-42) alone,following a 2-hour incubation at 37° C., demonstrated an initialfluorescence of 409+/−46 fluorescence units. During the 4 day incubationperiod, the levels of Aβ (1-42) amyloid fibrils as determined byThioflavin T fluorescence remained about the same (FIG. 10). Uncariatomentosa caused a significant dissolution/disruption of Aβ (1-42)amyloid fibril formation at all time points during the 4 day experiment.Since Aβ (1-42) is able to spontaneously form abundant amyloid fibrilsin solution, the initial inhibition by Uncaria tomentosa on Aβ (1-42)fibrils at 2 hours, actually reflected Uncaria tomentosa's ability todissolve pre-formed amyloid fibrils. At 2 hours of incubation, Uncariatomentosa caused a significant (p<0.001) 63% dissolution of Aβ (1-42)amyloid fibrils. A similar inhibition was observed at all time points(FIG. 8). By 4 days, a significant (p<0.001) 69% dissolution of Aβ(1-42) amyloid fibrils was still observed, indicating that thedissolving ability of Uncaria tomentosa on Aβ (1-42) amyloid fibrils waslong-lasting.

Confirmation of the inhibitory effect of Uncaria tomentosa extract on Aβ(1-42) amyloid fibrils was determined by Congo red staining of aliquotstaken from the above assay solutions. A marked reduction of congophilia(i.e. red/green birefringence when viewed under polarized light) wasobserved when Aβ amyloid fibrils were treated with Uncaria tomentosa for2 hours (not shown).

Example 9 Uncaria tomentosa Causes Dissolution of Islet Amyloid Fibrils(Amylin)

90% of patients with type II diabetes demonstrate the deposition andaccumulation of amyloid fibrils in the islets of Langerhans in thepancreas (Cooper et al, Proc. Natl. Acad. Sci. USA 84:8628-8632, 1987).This amyloid protein involved consists of a 37 amino acid protein knownas islet amyloid polypeptide or amylin. Islet amyloid is believed tocontribute to the destruction of the beta-cells of the pancreas, thuseventually leading many patients to become insulin-dependent (ie. type Idiabetes). Amylin has the ability to also form substantial amyloidfibrils immediately when placed in solution. The next study wastherefore implemented to determine whether Uncaria tomentosa also causesdissolution/disruption of another type of amyloidosis, and whether thiseffect was also long-lasting.

For this study, the method of Thioflavin T fluorometry as described inExample 5 was used. Briefly, 30 μl of 250 μM of human amylin (BachemInc, Torrance, Calif., USA; Lot #WL934) was incubated in microcentrifugetubes at 37° C. for 4 days (in triplicate), either alone, or in thepresence of 1.5 μl of Uncaria tomentosa (PTI-00703) (as described inExample 8).

As shown in FIG. 9, freshly suspended amylin alone, following a 2-hourincubation at 37° C., demonstrated an initial fluorescence of 1115+/−171fluorescence units. During the 4 day incubation period, the levels ofislet amyloid fibrils as determined by Thioflavin T fluorescence werefound to decrease reaching levels of 660+/−123 fluorescent units by 4days (FIG. 9), consistent with previous studies (Castillo et al,Diabetes 47:612-620, 1998). Uncaria tomentosa (PTI-00703) was found tocause an inhibition of amylin fibril formation at all time points duringthe 4 day experiment. Since amylin is able to spontaneously formabundant amyloid fibrils in solution, the initial inhibition by Uncariatomentosa on amylin fibrils at 2 hours, again reflected Uncariatomentosa's ability to dissolve/disrupt pre-formed amyloid fibrils. At 2hours of incubation, Uncaria tomentosa (PTI-00703) caused a significant(p<0.001) 72% dissolution of amylin fibrils, whereas by 4 days, asignificant (p<0.001) 80% dissolution of amylin fibrils was stillobserved (FIG. 9). This study demonstrated that Uncaria tomentosa iscapable of causing significant dissolution of other forms of amyloid(such as islet amyloidosis) and that this effect was again long-lasting.

Example 10 Methods of Isolation of the Amyloid Inhibitory Ingredientswithin Uncaria Tomentosa

Also disclosed are methods for isolation and identification of theactive amyloid inhibitory ingredients within Uncaria tomentosa obtainedfrom several different commercial sources. For isolation of the activeamyloid inhibitory ingredients from gelatin-coated capsules of Uncariatomentosa, 400 capsules (per run) containing dried plant materials arecollected into a 1 liter polypropylene container, to which 800 ml ofpropanol (Fisher, Fair Lawn, N.J., USA) is added and stirred overnightat 4° C. using a magnetic stirrer. For isolation of the active amyloidinhibitory ingredients of Uncaria tomentosa from solid tablets, thematerial in 400 tablets (per run) is ground up using a mortar andpestle, and extracted with propanol as described above. The extract isthen centrifuged at 17,000×g (Sorvall) for 20 minutes and thesupernatant is collected. The extraction and centrifugation procedure isrepeated 5 more times and the supernatants are collected, and thenconcentrated using a rotary evaporator (Rotavapor-R, Brinkman, Westbury,N.J., USA) at 60° C. When the volume is small enough (i.e. 500 mls), theextract is recentrifuged at 17,000×g to remove any insoluble materials.The supernatant obtained is then precipitated with 4 volumes ofpetroleum ether (Fisher) and the precipitate is collected followingcentrifugation at 3,000×g for 20 minutes using a Benchtop centrifuge.The pellet obtained is then washed twice by resuspension in 100 ml ofdistilled water, and then centrifuged again at 3,000×g for 20 minutes.The resulting pellet is then dissolved in 50-100 ml (depending on thesize of the pellet) of propanol and applied to a 300-ml silica columnequilibrated with propanol containing 0.5% (v/v) acetic acid. The samesolvent is then used to elute, and the fastest-moving yellowish-brownand/or orange colored fractions are collected with a fraction collector,and precipitated with 4 volumes of petroleum ether as described above.The pellet is then dissolved in acetonitrile/acetic acid/water(50:0.5:49.5; v/v/v) for HPLC injection.

The dissolved pellet is then divided into approximately 30 equalportions for injection into a HPLC (Hewlett-Packard 1050 series withmultiwavelength detector and HP 3396 series integrator, Hewlett-Packard,Wilmington, Del.) with a 1×25 cm C₁₈ column (218TP1010, Vydac, Hesperia,Calif.), maintained at 30° C. with a flow rate of 2 ml/min. Othercolumns may also be used for HPLC application, and the flow rates andeluates used to elute and purify the injected materials can be adjustedaccordingly. Using the column and flow rates as described above, afterinjection, the sample is eluted with gradients of A and B, such that 0%B for 5 min, 0-15% B from 5-10 min., 15-45% B from 10-70 min., and45-100% B from 70-85 min; where B=95% acetonitrile with 0.5% acetic acidin distilled water and A=5% acetonitrile with 0.5% acetic acid indistilled water. The effluents are monitored at 490 nm and 4 mlfractions are collected in a fraction collector and pooled peaks areobtained at various retention times, from 0 to 85 minutes. The fractionsare then concentrated by lyophilization after most of the acetonitrileis removed by rotary evaporation. 20-30 injections is required to obtainsufficient material (50-100 mg from 4 bottles of pills) for testing inrelevant assays, or for sample identification.

Another mode of isolation of the amyloid inhibitory active ingredientswithin Uncaria tomentosa obtained from different commercial sources, issimilar to that described above, except the use of the silica columnstep is omitted. This is a quicker method which also allows for muchgreater yield (i.e. 300-400 mg per preparation, instead of 50-100 mg perpreparation). For this method, following the extraction with propanol,precipitation and washing as described above, the washed pellets arethen dissolved in acetonitrile/acetic acid/water (50:0.5:49.5; v/v/v)for HPLC injection.

The dissolved pellet is then divided into approximately 40 equalportions for injection into a HPLC (Hewlett-Packard 1050 series withmultiwavelength detector and HP 3396 series integrator, Hewlett-Packard,Wilmington, Del.) with a 1×25 cm C₁₈ column (218TP1010, Vydac, Hesperia,Calif.), maintained at 30° C. with a flow rate of 2 ml/min. Afterinjection, the sample is eluted with gradients of A and B, such that 0%B for 5 min, 0-15% B from 5-10 min., 15-45% B from 10-70 min., and45-100% B from 70-85 min; where B=95% acetonitrile with 0.5% acetic acidin distilled water and A=5% acetonitrile with 0.5% acetic acid indistilled water. The effluents are monitored at 490 nm and 4 mlfractions are collected in a fraction collector and pooled peaks areobtained at various retention times, from 0 to 85 minutes. The fractionsare then concentrated by lyophilization after most of the acetonitrileis removed by rotary evaporation. 40-50 injections is required to obtainsufficient material (300-400 mg from 4 bottles of pills) for testing inrelevant assays, or for sample identification.

FIG. 10 demonstrates that this method is effective for separation,purification and identification of the active amyloid inhibitoryingredients within Uncaria tomentosa. As shown in FIG. 10A, reversephase HPLC monitored at 490 nm (due to activity correlating withyellowish-brown and/or orange color) and eluted with a gradient asdescribed above demonstrated that the Uncaria tomentosa extractcontained multiple ingredients that eluted off the column with a broadpeak observed at 13-45 minutes, and a peak observed at 80 minutes.Fraction 26, as an example, was re-injected onto HPLC and a symmetricalpeak was obtained (FIG. 10B) indicating the polydispersity of the broadpeak observed in FIG. 10A is not due to column artifact, but is due tothe presence of individual components within the Uncaria tomentosaextract. Peaks at 26 minutes and 80 minutes were then tested forpotential dissolution/disruption of pre-formed Alzheimer's Aβ amyloidfibrils (as described in Example 5) to determine if these peakscontained active amyloid inhibitory ingredients (FIG. 10C). Fraction at26 minutes (but not at 80 minutes) exhibited potent amyloid inhibitoryactivity causing an 85% dissolution/disruption of pre-formed Alzheimer'sdisease amyloid fibrils within a 2-hour period. Other peaks (from 13 to45 minutes retention time) were also obtained and tested as describedabove, and also found to contain amyloid inhibitory ingredients (notshown), suggesting that amyloid inhibitory ingredients were presentwithin the broad peak from 13 to 45 minutes retention time. This studyindicates that our method of isolation and testing can be used to purifyand isolate the active amyloid inhibitory ingredients within Uncariatomentosa extracts.

To identify the chemical structures and elemental composition of theactive amyloid inhibitory ingredients within Uncaria tomentosa variousanalyses can be implemented, known to those skilled in the art. Theseinclude, but are not limited to: a) use of a scanning electronmicroscope equipped with energy dispersive x-ray analyzer to detect andspatially map some elements present in each sample, b) high resolutionmass spectroscopy to determine molecular weight and elementalcomposition, 3) differential scanning calorimetry to determine meltingpoint, 4) FTIR spectroscopy to determine functional groups andcomparisons are made to spectral libraries, 5) proton and C¹³ NMRspectroscopy for further material characterization by providinginformation regarding the position of atoms relative to each other, and6) elemental analysis by combustion to determine the relative % ofcarbon, hydrogen and nitrogen.

Further Aspects and Utilizations of the Invention

Therapeutic Applications

One embodiment of the present invention is to formulate prior toadministration in a patient, a pharmaceutical formulation comprisingUncaria tomentosa (and/or its active ingredients) in one or morepharmaceutical acceptable carriers, diluents or excipients. In apreferred embodiment, a patient who has Alzheimer's disease, type IIdiabetes or any other amyloidosis, would orally consume commerciallyavailable Uncaria tomentosa in pill, tablet, caplet, soft and hardgelatin capsule, lozenge, vegicap, liquid drop, solution, syrup, teabag, and/or bark powder form.

In another preferred embodiment Uncaria tomentosa obtained commerciallyin any form could be further modulated using suitable carriers,excipients and diluents including lactose, dextrose, sucrose, sorbitol,mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyland propylhydroxybenzoates, talc, magnesium stearate and mineral oil.The formulations can additionally include lubricating agents, wettingagents, emulsifying and suspending agents, preserving agents, sweetingagents or flavoring agents. The compositions of the invention may beformulated so as to provide quick, sustained or delayed response of theactive ingredient after administration to the patient. The compositionsare preferably formulated in a unit dosage form, each dosage containingfrom about 1 to about 10,000 mg of Uncaria tomentosa (or its activeingredients), more usually about 500 to about 2,000 mg of Uncariatomentosa (or its active ingredients). However, it will be understoodthat the therapeutic dosage administered will be determined by thephysician in the light of the relevant circumstances including theclinical condition to be treated, the organ or tissues affected orsuspected to be affected with amyloid accumulation, and the chosen routeof administration. Therefore, the above dosage ranges are not intendedto limit the scope of the invention in any way. The term “unit dosageform” refers to physically discrete units suitable as unitary dosagesfor human subjects and other mammals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect, in association with a suitablepharmaceutical carrier.

The following formulation examples are illustrative only and are notintended to limit the scope of the invention in any way. For eachformulation provided as an example, lowering or raising of the Uncariatomentosa (or its active ingredients) concentration will cause aproportional lowering or raising of the other ingredients as indicated.Hard gelatin capsules may be prepared by using 500 mg of Uncariatomentosa (or its active ingredients), 400 mg of starch, and 20 mg ofmagnesium stearate. The above ingredients are mixed and filled into hardgelatin capsules in 920 mg quantities.

A tablet is prepared by using 500 mg of Uncaria tomentosa (or its activeingredients), 800 mg of microcrystalline cellulose, 20 mg of fumedsilicon dioxide and 10 mg of stearic acid. The components are blendedand compressed to form tablets each weighing 1230 mg.

An aerosol solution is prepared by using 0.25 active ingredient, 29.75ethanol, and 70 of propellent 22 (chlorodifluoromethane). The Uncariatomentosa (or its active ingredients) is mixed with ethanol. The mixtureis added to a portion of the Propellent 22, cooled to −30° C., andtransferred to a filling device. The required amount is then fed to astainless steel container and diluted with the remainder of thepropellent. The value units (listed above) are then fitted to thecontainer. Such an aerosol form of Uncaria tomentosa (or its activeingredients) may be useful for the treatment of amyloids involving thebrain (such as Alzheimer's disease, Down's syndrome, prion diseases etc)by using an aerosol or nasal spray. Previous studies have suggested thatin these central nervous system amyloidoses the initial form of entry ofa possible environmental agent which may be playing a role inpathogenesis may be derived from the outside world through the nasalpassages.

Tablets are made by using 240 mg of Uncaria tomentosa (or its activeingredients), 180 mg of starch, 140 mg of microcrystalline cellulose, 16mg of polyvinylpyrrolidone (as 10% in water), 18 mg of sodiumcarboxymethyl starch, 2 mg of magnesium stearate and 2 mg of talc(total=600 mg). Uncaria tomentosa (or its active ingredients), starchand cellulose are passed through a No. 45 mesh U.S. sieve and mixedthoroughly. The solution of polyvinylpyrrolidone is mixed with theresultant powders which are then passed through a No. 14 mesh U.S.sieve. The granules so produced are dried at 50° C. and passed through aNo. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesiumstearate and talc, previously passed through a No. 60 mesh U.S. sieve,are then added to the granules which, after mixing, are compressed on atablet machine to yield tablets each weighing 600 mg.

Capsules each containing 160 mg of medicant are made by using 160 mg ofUncaria tomentosa (or its active ingredients), 118 mg of starch, 118 mgof microcrystalline cellulose, and 4 mg of magnesium stearate (total=400mg). The Uncaria tomentosa (or its active ingredients), cellulose,starch and magnesium stearate are blended, passed through a No. 45 meshU.S. sieve, and filled into hard gelatin capsules in 400 mg quantities.

Suppositories each containing 225 mg of Uncaria tomentosa (or its activeingredients) are made by using 225 mg of Uncaria tomentosa (or itsactive ingredients), 2,000 mg of saturated fatty acid glycerides(total=2,225 mg). The Uncaria tomentosa (or its active ingredients) arepassed through a No. 60 mesh U.S. sieve and suspended in the saturatedfatty acid glycerides previously melted using the minimum heatnecessary. The mixture is then poured into a suppository mold of nominal2 g capacity and allowed to cool.

Suspensions each containing 50 mg of medicant per 5 ml dose are made byusing 50 mg of Uncaria tomentosa (or its active ingredients), 50 mg ofsodium carboxymethyl cellulose, 1.25 ml of syrup, 0.10 ml of benzoicacid solution, flavor, color, and purified water to total 5 ml. Themedicant is passed though a No. 45 mesh U.S. sieve and mixed with thesodium carboxymethyl cellulose and syrup to form a smooth paste. Thebenzoic acid solution, flavor and color are diluted with some of thewater and added, with stirring. Sufficient water is then added toproduce the required volume.

An intravenous formulation is prepared by using 250 mg of Uncariatomentosa (or its active ingredients), and 1000 mg of isotonic saline.The solution of the above ingredients is administered intravenously at arate of 1 ml per minute to a subject in need of treatment.

In a preferred embodiment the therapeutic compound of the invention canbe administered in any pharmaceutically acceptable vehicle. As usedherein “pharmaceutically acceptable vehicle” includes, but is notlimited to, any and all solvents, sterile liquids, such as water andoils, including those of petroleum, animal, vegetable or syntheticorigin, such as peanut oil, soybean oil, mineral oil, sesame oil and thelike, dispersion media, coatings, antibacterial and antifungal agents,isotonic and adsorption delaying agents, and the like which arecompatible with the activity of the compound and are physiologicallyacceptable to the subject. An example of a pharmaceutically acceptablevehicle is buffered normal saline (0.15 molar NaCl). The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. Supplementary active compounds can also be incorporated intothe compositions. Suitable pharmaceutical excipients include starch,glucose, lactose, sucrose, gelatin, malt, rice, fluor, chalk, silicagel, magnesium carbonate, magnesium stearate, sodium stearate, glycerolmonostearate, talc, sodium chloride, dried skim milk, glycerol,propylene, glycol, water, ethanol and the like. These compositions cantake the form of solutions, suspensions, tablets, pills, capsules,powders, sustained-release formulations and the like.

In the methods of the invention, amyloid formation, deposition,accumulation and/or persistence in a subject is inhibited byadministrating Uncaria tomentosa (or its active ingredients) in atherapeutic dosage to the subject. The term subject is intended toinclude living organisms in which amyloidosis can occur. Examples ofsubjects include humans, monkeys, cows, dogs, sheep, cats, mice, rats,and transgenic species thereof. Administration of the compositions ofthe present invention to a subject to be treated can be carried outusing known procedures, at dosages and for periods of time effective toinhibit amyloidosis in the subject. An effective amount of thetherapeutic compound necessary to achieve a therapeutic effect may varyaccording to factors such as the amount of amyloid already deposited atthe organ or tissue site in the subject, the age, sex and weight of thesubject, and the ability of the therapeutic compound to inhibit amyloidformation, deposition, accumulation, persistence, and/or to causedissolution of pre-formed amyloid in the subject. Dosage regimens cantherefore be adjusted to provide the optimum therapeutic response. Forexample, several divided doses may be administered daily or the dose maybe proportionally reduced as indicated by the needs of the therapeuticsituation. A non-limiting example of an effective dose range for Uncariatomentosa (or its active ingredients) is between 10 and 1000 mg/kg ofbody weight/per day, but preferably 10 to 100 mg/kg of body weight.

Different modes of delivery of Uncaria tomentosa (or its activeingredients) may be used. Accordingly, a preferred route ofadministration is oral administration. Alternatively, Uncaria tomentosa(or its active ingredients) may be administered by other suitable routessuch as subcutaneous, intravenous, intraperitoneal, all routesadministered by injection. Depending on the route of administration, theactive compound may be coated in a material to protect the compound fromthe action of acids and other natural conditions which may inactivatethe compound.

To administer Uncaria tomentosa (or its active ingredients), it may benecessary to coat the compound with, or co-administer the compound with,a material to prevent its activation. For example, the therapeuticcompound may be administered to a subject in an appropriate carrier, forexample, liposomes or a diluent. Pharmaceutically acceptable diluentsinclude saline and aqueous buffer solutions. Liposomes includewater-in-oil-in-water CGF emulsions as well as conventional liposomes.

The Uncaria tomentosa (or its active ingredients) may also beadministered parenterally or intraperitoneally. Dispersions can beprepared in glycerol, liquid polyethylene glycols, and mixtures thereofand in oils. Under ordinary conditions of storage and use, thesepreparations may contain a preservative to prevent the growth ofmicroorganisms.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions or dispersions and sterile powders for the preparationof sterile injectable solutions or dispersion. In all cases, thecomposition must be sterile and must be fluid to the extent that easyuse in the syringe exists. It must be stable under the conditions ofmanufacture and storage and must be preserved against the contaminatingaction of microorganisms such as bacteria and fungi. The vehicle can bea solvent or dispersion medium containing, for example, water, ethanol,polyol (for example glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), suitable mixtures thereof, and vegetable oils.The proper fluidity can be maintained, for example, by the use of acoating such as lecithin, by the maintenance of the required particlesize in the case of dispersion and by the use of surfactants. Preventionof the action of microorganisms can be achieved by various antibacterialand antifungal agents, for example, prabens, chlorobutanol, phenol,ascorbic acid, thimerosal, and the like. In many cases, it will bepreferable to include isotonic agents, for example, sugars, sodiumchloride, or polyalcohols such as mannitol and sorbitol, in thecomposition. Prolonged absorption of the injectable compositions can bebrought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate or gelatin.

Sterile injectable solutions can be prepared by incorporating thetherapeutic compound in the required amount in an appropriate solventwith one or a combination of ingredients enumerated above, as required,followed by filtered sterilization. Generally, dispersions are preparedby incorporating the therapeutic compound into a sterile vehicle whichcontains a basic dispersion medium and the required other ingredientsfrom those enumerated above. In the case of sterile powders for thepreparation of sterile injectable solutions, the preferred methods ofpreparation are vacuum drying and freeze-drying which yields a powder ofthe therapeutic agent plus any desired ingredients from a previouslysterile-filtered solution thereof.

The Uncaria tomentosa (or its active ingredients) for Alzheimer'sdisease and other central nervous system amyloidoses may be optimized tocross the blood-brain barrier. Methods of introductions include but arenot limited to systemic administration, parenteral administration i.e.,via an intraperitoneal, intravenous, perioral, subcutaneous,intramuscular, intraarterial, intradermal, intramuscular, intranasal,epidural and oral routes. In a preferred embodiment, Uncaria tomentosa(or its active ingredients) may be directly administered to thecerebrospinal fluid by intraventricular injection. In a specificembodiment, it may be desirable to administer Uncaria tomentosa (or itsactive ingredients) locally to the area or tissue in need of treatment;this may be achieved by, for example, and not by way of limitation,local infusion during surgery, topical application, by injection, byinfusion using a cannulae with osmotic pump, by means of a catheter, bymeans of a suppository, or by means of an implant.

In yet another embodiment Uncaria tomentosa (or its active ingredients)may be delivered in a controlled release system, such as an osmoticpump. In yet another embodiment, a controlled release system can beplaced in proximity to the therapeutic target, ie. the brain, thusrequiring only a fraction of the systemic dose.

With regard to systems and components above referred to, but nototherwise specified or described in detail herein, the workings andspecifications of such systems and components and the manner in whichthey may be made or assembled or used, both cooperatively with eachother and with the other elements of the invention described herein toeffect the purposes herein disclosed, are all believed to be well withinthe knowledge of those skilled in the art. No concerted attempt torepeat here what is generally known to the artisan has therefore beenmade.

INDUSTRIAL APPLICABILITY

Use of extracts from the inner bark and root parts of Uncaria tomentosa,and use of the ingredients contained within the various commercialpreparations of Uncaria tomentosa, benefit human patients withAlzheimer's disease and other amyloidoses due to Uncaria tomentosa'snewly discovered ability to inhibit amyloid fibril formation, inhibitamyloid fibril growth, inhibit amyloid-proteoglycan interactions,inhibit amyloid-glycosaminoglycan interactions, and cause dissolutionand/or disruption of preformed amyloid fibrils.

In compliance with the statute, the invention has been described inlanguage more or less specific as to structural features. It is to beunderstood, however, that the invention is not limited to the specificfeatures shown, since the means and construction shown comprisepreferred forms of putting the invention into effect. The invention is,therefore, claimed in any of its forms or modifications within thelegitimate and valid scope of the appended claims, appropriatelyinterpreted in accordance with the doctrine of equivalents.

1. A method of treating an amyloid disease in a patient, comprisingadministering to the patient an amount of plant matter from Uncariatomentosa.
 2. The method claim 1 wherein the plant matter isadministered orally.
 3. The method claim 1 wherein the plant matter isadministered by aerosol spray.
 4. The method claim 1 wherein the plantmatter is administered in a parenterally injectable or infusible form.5. The method of claim 1 wherein the amyloid disease is type IIdiabetes.
 6. A method for reducing, disrupting, dissolving or inhibitingislet amyloid and amylin fibrils in a patient comprising administrationof plant matter from Uncaria tomentosa.
 7. The method claim 6 whereinthe plant matter is administered orally.
 8. The method claim 6 whereinthe plant matter is administered by aerosol spray.
 9. The method claim 6wherein the plant matter is administered in a parenterally injectable orinfusible form.